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  Exogenous and endogenous cannabinoids have been reported to modulate 
functional activities of macrophages.  It is recognized that macrophages express primarily 
the CB2 cannabinoid receptor, but recent studies indicate that its expression is differential 
in relation to activation state with maximal levels occurring when cells are in 
“responsive” and “primed” states.  The functional activities of macrophages when in 
these states of activation are the most susceptible to the action of cannabinoids, at least in 
terms of a functional linkage to the CB2.  To assess the effect of cannabinoid treatment on 
macrophage chemotaxis and test the hypothesis that cannabinoids inhibit the chemotactic 
response of macrophages and microglia to endogenous and exogenous, pathogen-derived 
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stimuli, primary murine peritoneal macrophages and neonatal rat microglia were used.  
Chemotaxis assays and scanning electron microscopy studies demonstrated that 
cannabinoids inhibit chemotaxis, a signature activity attributed to “responsive” 
macrophage-like cells, to the endogenous chemokine RANTES (Regulated upon 
Activation Normal T-cell Expressed and Secreted) and to Acanthamoeba conditioned 
medium containing secreted proteases.  The partial agonist delta-9-tetrahydrocannabinol 
(THC), administered in vitro, inhibited the chemotactic response of peritoneal 
macrophages to the chemokine RANTES and to Acanthamoeba conditioned medium.  In 
vivo treatment with THC also resulted in inhibition of the in vitro chemotactic response 
of murine peritoneal macrophages to RANTES and amoebic conditioned medium.  
Pharmacological studies employing cannabinoid receptor agonists and antagonists 
demonstrated the involvement of CB2 in cannabinoid-mediated inhibition of peritoneal 
macrophage chemotaxis to RANTES and Acanthamoeba conditioned medium, implying 
that signaling through cannabinoid receptors may desensitize chemokine receptors.  
Treatment with cannabinoids had no apparent effect on chemokine receptor mRNA 
levels, but did enhance CCR5 protein phosphorylation.  Macrophage migration to 
Acanthamoeba conditioned medium may involve activation and signaling through 
protease activated receptors (PARs), as pathogen-derived proteases have been shown to 
activate PARs and initiate cellular migration; however, further studies are required to 
demonstrate PAR activation by amoebic conditioned medium and to assess the effects of 
cannabinoids on PAR signaling.       
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Acanthamoeba are opportunistic pathogens that cause Granulomatis amoebic 
encephalitis, an infection of the CNS that is often fatal.  THC treatment has been shown 
to increase mortality to Acanthamoeba infections and is characterized by an absence of 
granuloma formation.  We hypothesize that inhibitory effect of THC on macrophage 
migration may be a key factor in cannabinoid-mediated immunosuppression.  To assess 
the effect of cannabinoids on microglial migration to Acanthamoeba conditioned 
medium, chemotaxis assays were performed using primary rat microglia treated with 
cannabinoids. These studies demonstrated that cannabinoids inhibit microglial 
chemotaxis to amoebic conditioned medium.   
Furthermore, the studies demonstrate that cannabinoids, acting through 
cannabinoid receptors, may cross-talk with a diverse array G-protein coupled receptors so 
as to modulate responsiveness of macrophage and macrophage-like cells.     
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 Introduction 
 
Cannabis is one of the oldest and most widely used drugs in human history, with 
references to its use in ancient Chinese civilization dating to 2737 BC (Li, 1974).  
Medicinal use of cannabis continued freely in Western countries throughout the 1800s 
and into the mid-1900s.  However, in 1942, cannabis was withdrawn from the United 
States Pharmacopoeia (USP), a compendium published annually by the United States 
Pharmacopoeia Convention providing standardization of therapeutic drugs.  Great Britain 
and many other European countries prohibited cannabis use in 1971, by adopting policies 
proposed by the United Nations-led Convention on Psychotropic Substantces (Ben Amar, 
2006).   
The marijuana plant (Cannabis sativa) contains over 450 known chemicals 
including more than 60 pharmacologically active compounds called cannabinoids.  
Cannabinoids have been shown to elicit a variety of physiological effects including 
impairments of short-term memory, attention span, and motor function, in addition to 
numerous psychological effects including paranoia, altered perception, and hallucinations 
(Martin, 1986).  Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive 
component in marijuana.  This exogenous cannabinoid exerts a variety of modulatory 
effects on the immune system, the majority of which have been reported to be 
immunosuppressive (Klein et al., 1998; Cabral and Dove Pettit, 1998; Cabral and Staab, 
2005).  In this capacity, THC affects a diverse array of immune cell types, including B 
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lymphocytes (Klein et al., 1985), Natural Killer cells (Specter et al., 1986), T 
lymphocytes (Zimmerman et al., 1977), macrophages (Raz and Goldman, 1976; 
Friedman et al., 1986) and macrophage-like cells (Puffenbarger et al., 2000).  
Cannabinoid effects on cellular systems can occur by both receptor-mediated and non-
receptor-mediated modes (Makriyannis et al., 1990; Felder et al., 1992; Berdyshev et al. 
2001; Price et al., 2004).  In terms of receptor-mediated action, two cannabinoid 
receptors have been identified and linked to THC effects on immune function.  The first 
of these, CB1, is found at highest levels in the central nervous system (CNS) with 
expression in the hippocampus, basal ganglia, cerebral cortex, amygdala and cerebellum 
correlating with observed neurological effects of cannabinoids (Matsuda et al., 1990; 
Galiégue et al., 1995; Herkenham et al., 1991).  CB1 is present in the testis (Galiégue et 
al., 1995) and also at low levels in various immune cells (Galiégue et al., 1995; Daaka et 
al., 1996; Waksman et al., 1999). The second receptor, CB2, is found primarily in 
immune cells (Munro et al., 1993; Galiégue et al., 1995) and appears to play a major role 
in immune modulation (Klein et al., 1998; Cabral and Dove Pettit, 1998; Cabral and 
Staab, 2005).  Both cannabinoid receptors are members of a large receptor superfamily 
known as G-protein coupled receptors (GPCRs), and characteristically have seven 
transmembrane domains and initiate cellular signal transduction through coupling with G 
proteins.  Both CB1 and CB2 receptors are coupled to Gi/o proteins. Cannabinoid receptor 
signaling through these G proteins inhibits cyclic adenosine 3’,5’-monophosphate 
(cAMP) and subsequent activation of protein kinase A (PKA) and activates mitogen 
activated protein kinase (MAP kinase)(Berdyshev, 2000).  Cannabinoid receptor 
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signaling involves numerous second messengers and converges with multiple signal 
transduction pathways that are critical in the immune response.   
Of the various immune cell populations affected by THC and other cannabinoids, 
macrophages and macrophage-like cells appear to be a major target (Munro et al., 1993; 
Cabral et al., 1995; Waksman et al., 1999; Puffenbarger et al., 2000). Ultrastructural 
abnormalities have been observed in alveolar macrophages of humans who have been 
heavy users of marijuana (Mann et al., 1971) and in peritoneal macrophages of mice 
exposed in vitro to various concentrations of THC (Raz and Goldman, 1976).  Various 
functional defects of alveolar and peritoneal macrophages from humans, rats or mice 
following in vivo or in vitro exposure to marijuana or THC also have been reported. 
These alterations have included decreases in cell motility, ability to spread in vitro, 
release of β-glucuronidase, phagocytosis of yeast particles, and inactivation of 
Staphylococcus aureus and S. albus (Huber et al., 1975; Chari-Briton, 1976; McCarthy et 
al., 1976; Drath et al., 1979; Huber et al., 1978; Lopez-Cepero et al., 1986; Specter et al., 
1991; Tang et al., 1992).  In addition, THC has been reported to affect macrophage 
processing of soluble protein antigens (McCoy et al., 1995; 1999).  THC and other 
cannabinoids also have been shown to modulate the production of cytokine and 
chemokines by peripheral macrophages as well as microglia, the resident macrophages 
within the CNS (Klein et al., 2000; McCoy et al., 1995; Puffenbarger et al., 2000; 
Srivastava et al., 1998; Waksman et al., 1999; Zheng et al., 1992).   
 Macrophages play a critical role in both innate immunity as well as cell-mediated 
immunity.  The primary functions of these cells are to navigate to sites of tissue damage 
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or infection, phagocytose cellular debris or pathogens, and stimulate lymphocytes and 
other immune cells to respond to the pathogen.  Integral to this process is the recruitment 
of macrophages, which occurs early in the inflammatory process and is mediated by 
specific chemical stimuli.  This migratory activity is distinctive from that of stimulus-
independent random cellular motion (Lauffenburger and Horwitz, 1996; Mitchison and 
Cramer, 1996).  The two major modes of stimulus-dependent cellular motility are 
chemokinesis and chemotaxis. Chemokinesis is a process whereby cells exhibit random, 
non-directional motion that is dependent on a chemical stimulant (Becker, 1977; Keller et 
al., 1978).  On the other hand, chemotaxis is a process in which cell motility is directed 
toward a concentration gradient of a chemical stimulant (Harris, 1953, 1954; Jin and 
Hereld, 2006; Kehrl, 2006).  In this chemotactic process, macrophage interaction with 
chemoattractants not only initiates rapid and directed movement, but also is associated 
with a complex array of cellular events that includes changes in ion fluxes, alterations in 
integrin expression and avidity, production of superoxide anions, and secretion of 
lysosomal enzymes (Murdoch and Finn, 2000).  “Classical” chemoattractants include 
bacterial-derived N-formyl peptides, the complement fragment peptides C5a and C3a, 
and lipids such as leukotriene B4 and platelet-activating factor (Schiffman et al., 1975; 
Goldman and Goetzl, 1982; Hanahan, 1986; Gerard and Gerard, 1994).  Chemokines 
represent a second group of chemoattractants.  These secreted cytokines range from 8- to 
17-kD molecular mass and are selective for leukocytes in vitro, in addition to eliciting the 
accumulation of inflammatory cells in vivo (Baggiolini et al., 1994, 1997; Kim, 2004; Le 
et al., 2004).  Chemokines have been categorized into four groups on the basis of their N-
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terminal cysteine motifs - CXC (α-chemokines), CC (β-chemokines), CX3X (δ-
chemokines), and C (γ-chemokines) (Murphy, 2000) (Table 1).  As in the case for 
cannabinoid receptors, the specific effects of chemokines on target cells are mediated by 
G protein-coupled receptors (Murdoch and Finn, 2000; Charo and Ransohoff, 2006).  
Ligation of chemokines with their cognate receptors initiates a series of signal 
transductional events that results in regulation of leukocyte trafficking in inflammation, 
tissue injury, tumor development and host response to infection (Charo and Ransohoff, 
2006).  Correlative to chemokine nomenclature, four families of chemokine receptors 
have been defined based on the chemokines they bind (CC, CXC, CX3C, or C), followed 
by R for receptor and a number indicating the order in which they were discovered 
(Murphy, 2002) (Table 2).   
G protein coupled receptors have been reported to cross-talk through a process 
known as heterologous desensitization.  Chemokine receptor activity has been shown to 
be inhibited by the activation of numerous classes of GPCRs including opioid receptors 
and adenosine receptors (Zhang and Oppenheim, 2005).  Activation of one type of GPCR 
can result in the phosphorylation of cytosolic C-terminal residues of other GPCRs by G 
protein coupled receptor kinases (GRKs) or other second messenger kinases.  
Phosphorylated receptors are unable to couple to G proteins; therefore, subsequent ligand 
binding does not initiate signal transduction.  GPCR crosstalk may play an important role 
in the integration of diverse systems and the overall maintenance of immune homeostasis.  
Alternately, dysregulation of this crosstalk through the addition of exogenous compounds 
may constitute a significant element of drug-related immunosuppression.  For example, 
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opioid desensitization of chemokine receptors has been directly implicated in 
immunosuppression consequent of opioid use (Rogers et al., 2000).  Macrophages also 
play an important role in pathogen recognition and clearance, and appear to be the 
primary effector cell in the immune response against Acanthamoeba infection (Marciano-
Cabral et al., 2003).  The free-living amoebae of the genus Acanthamoeba are 
opportunistic pathogens with ubiquitous distribution.  These microorganisms have been 
isolated world-wide from varied environments including soil, sewage, hospitals, 
seawater, drinking water treatment plants, and contact lenses (Marciano-Cabral et al., 
2003).  Acanthamoeba spp. are also the causative agents of granulomatous amebic 
encephalitis (GAE), amebic keratitis and cutaneous amebiasis in humans.
 Granulomatous amebic encephalitis is a progressive infection of the CNS that is 
often fatal, especially in the immunocompromised.  Acanthamoeba access to the CNS 
may occur through the olfactory neuroepithelium following inhalation through the nasal 
passages or via hematogenous spread from a cutaneous lesion (Martinez et al., 1985). 
Pathological findings from fatal cases of GAE reveal inflammation and severe 
hemorrhagic necrosis. The latter is presumably caused by a combination of direct 
destruction of brain tissue by feeding amoeba, secretion of lytic factors by amoeba, and 
prolonged induction of inflammatory cytokines such as tumor necrosis factor-alpha 
(TNF-α) and interleukin-1 (IL-1) (Marciano-Cabral et al., 2000). 
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Table 1 – CC Chemokine Nomeclature 
 
Symbol Alternate Name(s) 
CCL1  TCA3, I-309 
CCL2  MCP-1 (monocyte chemotactant protein-1) 
CCL3  MIP-1α (macrophage inflammatory protein1-alpha) 
CCL4  MIP-1β (macrophage inflammatory protein1-beta) 
CCL5 RANTES (Regulated upon activation normal T cell expressed and 
secreted) 
CCL6  C10, MRP-1 (MIP-related protein-1) 
CCL7  MCP-3 (monocyte chemotactant protein-3) 
CCL8  MCP-2 (monocyte chemotactant protein-2) 
CCL9 MIP-1γ ( macrophage inflammatory protein1-gamma), MRP-2 (MIP-
related protein-2) 
CCL10 now CCL9 
CCL11 eotaxin 
CCL12 MCP-5 (monocyte chemotactant protein-5) 
CCL13 MCP-4 (monocyte chemotactant protein-4) 
CCL14 HCC1 (human CC chemokine 1) 
CCL15 MIP-5 (macrophage inflammatory protein-5), HCC-2  
CCL16 LEC (liver expressing chemokine), Mnt-1 (monotactin-1) 
CCL17 TARC (thymus and activation related chemokine) 
CCL18 MIP-4 (macrophage inflammatory protein-4), PARC (pulmonary and 
activation regulated chemokine) 
CCL19 MIP-3β (macrophage inflammatory protein3-beta) 
CCL20 MIP-3α (macrophage inflammatory protein3-alpha), LARC (liver 
activation regulated chemokine 
CCL21 6Ckine, SLC (secondary lymyphoid-tissue chemokine) 
CCL22 MDC (macrophage derived chemokine) 
CCL23 MIP-3 (macrophage inflammatory protein-3), MPIF-1 (myeloid progenitor 
inhibitory factor-1) 
CCL24 eotaxin-2, MPIF-2 (myeloid progenitor inhibitory factor-2) 
CCL25 TECK 
CCL26 MIP-4α (macrophage inflammatory protein4-alpha), eotaxin-3 
CCL27 CTAK (cutaneous T-cell attracting chemokine) 
CCL28 MEK (mucosal-associated epithelial chemokine) 
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Table 2- CC Chemokines and Chemokine Receptors 
 
 
Receptor  Ligand(s)    Primary Functions 
 
CCR1                          CCL3, CCL5, CCL7,   T cell and monocyte   
CCL8, CCL13-16, CCL23  migration, inflammation 
 
CCR2                          CCL2, CCL8, CCL7,    T cell and monocyte 
CCL13    migration, inflammation 
 
CCR3                          CCL5, CCL7, CCL8,    Eosinophil, basophil, T cell 
CCL11, CCL13, CCL15,   migration 
CCL24, CCL26 
 
CCR4                          CCL17, CCL22   T cell and monocyte 
   Migration 
 
CCR5                          CCL3, CCL4, CCL5,    T cell and monocyte  
CCL8, CCL14   migration 
 
CCR6                          CCL20   Dendritic cell migration 
 
CCR7                          CCL19, CCL21   T cell and dendritic cell 
  migration 
 
CCR8                          CCL1, CCL4, CCL14   T cell trafficking 
 
CCR9                          CCL25   T cell trafficking   
 
CCR10                        CCL26-28   T cell trafficking 
 
 
Adapted from Murphy et al., 2002.      
   
    9
 THC has been shown to increase host susceptibility to a wide variety of 
pathogenic bacteria, protozoa, and viruses (reviewed in Cabral and Dove Pettit, 1998).  
Experiments using an in vivo animal model of Acanthamoeba infections performed by 
Marciano-Cabral et al. (2001) demonstrated that (B6C3)F1 mice injected with THC and 
exposed to Acanthamoeba intranasally had a higher incidence of mortality compared with 
vehicle treated animals.  While macrophages are thought to be the primary immune cell 
involved in host response to Acanthamoeba infection, the specific effect of THC on 
macrophage function has not been fully defined.  Histopathological analysis of brain 
slices from mice and humans with GAE show the formation of immune cell granulomas, 
containing macrophages and neutrophils, surrounding the amoebae (Marciano-Cabral et 
al., 2003; Cabral et al., in press 2007).  These granulomas are conspicuously absent in 
THC-induced immunosuppression, indicating that THC may impair the macrophage 
migratory response.   
The goal of the present study was divided into three main objectives.  Initially, we 
sought to assess the effect of THC on the chemotactic response of murine peritoneal 
macrophages to RANTES/CCL5 (Regulated upon Activation Normal T cell Expressed 
and Secreted/ chemokine (C-C motif) ligand 5).  Next, we proposed to examine the 
migratory response of peritoneal macrophages to Acanthamoeba, and determine whether 
THC affected this response.  Finally, to expand the relevance of the previous studies we 
assessed the effect of THC on the migration of primary rat microglial cells to 
Acanthamoeba, thereby more closely modeling the process of a natural infection and 
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identifying a potential mechanism of THC-induced immunosuppression in CNS 
infections    
We demonstrate that THC inhibits the chemotactic response of murine peritoneal 
macrophages to RANTES, a cognate chemokine receptor ligand.  The inhibitory effect 
was shown to be linked functionally to the CB2, suggesting that cannabinoids can signal 
through this receptor to trans-deactivate the chemokine receptor-mediated migratory 
response.  Additionally, we show that peritoneal macrophages and microglia, the 
macrophages of the CNS, exhibit migration to Acanthamoeba and that this response is 
inhibited by THC.  While the immunosuppressive effects of THC are extensive and likely 
involve numerous cell types and complex mechanisms and/or pathways, these studies 
serve to define, at least in part, the mechanism by which THC suppresses macrophage 
function.   
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Materials and Methods 
 
 
Amoeba 
 Acanthamoeba culbertsoni (American Type Culture Collection, ATCC 30171, 
Manassas,VA) were cultured axenically in PYG medium containing 2% proteose 
peptone, 0.2% yeast extract, and 0.1M glucose at 37 oC.   
 Acanthamoeba sp. strain JH1 was isolated from an immunosuppressed patient at 
Johns Hopkins Hospital (Marciano-Cabral et al., 2003b).  This clinical isolate was 
obtained postmortem from a cutaneous lesion of an immune suppressed patient who had 
undergone a prior renal transplant.  Transmission electron microscopy studies identified 
the presence of gram negative rods within the cytoplasmic vacuoles of the amoeba.  
Acanthamoeba JH1 were cultured in Oxoid medium with serum and hemin and without 
antibiotics.   
 Amoeba conditioned medium (ACM) was obtained by culturing amoeba in PYG 
medium in 1L flasks at 37oC with constant agitation for 4 days.  The amoebae were 
harvested by centrifugation.  The pelleted amoebae (109) were suspended in 5 ml Hank’s 
Balanced Salt Solution (HBSS) and incubated at 37oC for 24 h.  The following day the 
cultures were centrifuged at 489 x g (2,500 RPM, Eppendorf 5810 R) for 20 min.  The 
supernatant was decanted and centrifuged again at 16100 x g (13,100 RPM, Eppendorf  
5415 D) for 10 min to remove any remaining debris and was designated amoeba 
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conditioned medium (ACM).  Protein concentration of ACM was determined by 
Bradford assay (Bradford, 1976).   
 
Cells 
Thioglycollate-elicited peritoneal macrophages were obtained by injecting 
BB6C3(F1) or C57BL/6 mice intraperitoneally with 1 ml 10% Brewer’s yeast 
thioglycollate. Five days later, cells were harvested by aseptic peritoneal lavage with 
HBSS supplemented with penicillin [200U/ml] and streptomycin [200 μg/ml].  The 
peritoneal exudate cells were screened for purity for macrophages by FACScan analysis 
using monoclonal antibody for the murine macrophage marker F4/80 (Serotec, 
Kidlington, Oxford, UK).  Cells that were greater than 95% positive for F4/80 were used 
in studies. Macrophages (10  /ml) in RPMI 1640 medium (Cellgro, Herndon, VA) 
lacking serum and supplemented with 1% L-glutamine, 1% nonessential amino acids, 1% 
MEM vitamins, 0.01M HEPES and penicillin [100 U/ml]/streptomycin [100 
μg/ml]/fungizone [0.25 μg/ml]) were used in chemotaxis assays.  
7
Primary microglia cultures were prepared from neonatal Sprague-Dawley (Zivik-
Miller Laboratory, Zeleinople, PA) rat pups (1-2 days postpartum).  Following sacrifice, 
the cerebral cortices were isolated and placed in dissection saline containing 2.8% (v/v) 
stock dissection HEPES (352mM HEPES in dH2O), 5% stock dissection saline (137 mM 
NaCl, 5.3mM KCl, 0.17mM Na2PO4-7H2O, 0.22 mM KH2PO4, and 0.0012g/L Phenol 
Red in dH2O), 5% stock Glucose/Sucrose solution (6g/L glucose, 15 g/L sucrose), and 
penicillin [100 U/ml]/streptomycin [100 μg/ml].  Subsequently, the surrounding 
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meninges were removed, the remaining tissue manually disrupted and incubated with 
porcine pancreas derived trypsin (Sigma) for 10 min.  The tissue homogenate was 
suspended in DMEM containing 10% FBS and supplemented with 1% L-glutamine, 1% 
nonessential amino acids, 1% MEM vitamins, 0.01M HEPES, and penicillin 
(100U/mL)/streptomycin (100μg/mL) and fungizone (0.25 μg/mL) (complete DMEM) 
and filtered through a 70μm nylon cell strainer.  The strained suspension then was 
centrifuged at 1,000 RPM for 30 min at 4oC.  The mixed glial cell suspension containing 
astrocytes and microglia were seeded in 172cm2 tissue culture flasks (Greiner, Monroe, 
NC) and cultured at 37oC and 5% CO2 in complete DMEM medium.  The medium was 
replaced the following day with warmed complete DMEM and the cells allowed to grow 
for 14-21 days.  To recover primary microglia, the mixed glial cultures were agitated at 
180 RPM on an orbital shaker for 2 h at 37oC.  Alternately, primary rat mixed glial 
cultures containing astrocytes and microglia were obtained from Dr. Jameel Dennis, 
Department of Anatomy and Neurobiology following immunopanning using anti-
oligodendrocyte antibodies to isolate oligodendrocytes from cortical cultures (Fox et al., 
2003).   
 
Mice 
Six to eight-week old female (B6C3)F1 and C57BL/6 mice were obtained from Taconic 
Laboratories (Hudson, NY). CB2 (-/-) mice on a C57BL/6 background were obtained 
from Dr. Nancy E. Buckley (California Polytechnic University, Pomona, CA).  CB2 
deficiency was confirmed by polymerase chain reaction (PCR) as described (Buckley et 
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al., 2000; Chuchawankul et al., 2004).  Phenotypic characterization was performed by 
Buckley et al. (2000) and reportedly CB2 knockout mice are healthy and fertile with no 
significant alterations in immune cell populations as measured by FACS analysis, 
indicating that the knockout did not affect immune cell development or differentiation.  
Therefore, peritoneal macrophages from these knockout mice should be phenotypically 
comparable to wild type peritoneal macrophages and any effect, or absence thereof, of 
cannabinoids on macrophage immune function should be the result of a measurable 
scientific phenomenon and not an artifact.   
Animals were quarantined for one week prior to initiation of experiments and 
were used as a source of peritoneal macrophages.  All animal procedures were conducted 
in accordance with guidelines established by the Virginia Commonwealth University 
Institutional Animal Care and Use Committee (IACUC).  
 
Drugs 
  Delta-9-tetrahydrocannabinol (THC; CB1 Ki = 40.7nM; CB2 Ki= 36.4 nM), a low 
efficacy agonist for CB1 and CB2, was obtained from the National Institute on Drug 
Abuse (Rockville, MD). Additional cannabinoid analogs included the CB1 and CB2 high 
efficacy agonist CP55940 (CB1 and CB2 Ki = 1.37 nM) and the highly selective CB2 
ligand O-2137-2 (CB1 Ki = 2,700nM, CB2 Ki = 11nM).  The highly selective CB1 agonist 
ACEA (CBB1 Ki = 1.4 nM) that displays > 1,400-fold selectivity over CB2 was purchased 
from Tocris Cookson, Inc. (Ellisville, MO).  The CB1 and CB2 antagonists SR141716 
(CB1 Ki =11.8 nM, CB2 Ki = 13,200 nM) and SR144528 (CB1 Ki = 437nM, CB2 Ki = 
0.6nM), respectively, were obtained from Sanofi Recherche (Montpellier, France).   
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The review by Howlett et al. (2002) provides a comprehensive summary of cannabinoid 
receptor ligand binding affinities and methodologies and was utilized in preparation of 
Table 3.  Ligand binding data was obtained from in vitro radiolabeled ligand 
displacement assays performed on membrane preparations from either from cell lines 
transfected with cloned receptors or tissues (brain tissue preparations for CB1 or spleen 
tissue preparations for CBB2).   
Stock solutions of cannabinoids (10-2M) were prepared in 100% ethanol and 
stored at –20oC.  Experimental concentrations were obtained by dilution of cannabinoid 
stock solutions in assay medium (RPMI-1640 for peritoneal macrophages or DMEM for 
primary microglia) to yield a final ethanol concentration of 0.01%.  Vehicle controls 
consisted of 0.01% ethanol in medium.  
 
Chemotaxis Assay 
 Chemotaxis was measured using transwell inserts pre-loaded in 35 mm standard 
tissue culture plates (Corning Inc., Corning, NY), in which the upper and lower 
compartments were separated by a polycarbonate filter with 8 μm pores (Corning Inc., 
Corning, NY).  Peritoneal macrophages (1x107 /ml) were pre-incubated in RPMI 1640 
lacking serum and containing vehicle (0.01% ethanol) or cannabinoid (10-6M – 10-12M) 
for 3 h at 4oC.  This time regimen for drug exposure was obtained through initial 
optimization experiments.  Serum was omitted from the culture medium since it contains 
lipids and other factors that have the capacity to stimulate macrophage migration that 
could confound interpretation of migratory responses as attributable to RANTES.  For  
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Table 3- Cannabinoid Receptor Ligands 
 
 
Cannabinoid   Classification   Dissociation Constant (Ki) 
        CB1ki  CB2 ki
 
THC   Low efficacy CB1/CB2 agonist 40.7nM 36.4 nM 
 
CP55940  High efficacy CB1 and CB2 agonist 1.37nM 1.37nM 
 
ACEA   CB1 selective agonist   1.4nM  >2000nM 
 
O-2137  CB2 selective agonist   2,700nM 11nM 
 
SR141716A (SR1) CB1 selective antagonist  11.8nM 13200nM 
 
SR144528 (SR2) CB2 selective antagonist  437nM  0.6nM 
 
 
 
Abbreviations-  THC, (δ9-tetrahydrocannabinol); CP55940, ((-)-cis-3-[2-Hydroxy-4-(1,1-
dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol); ACEA, (N-(2-Chloroethyl)-
5Z,8Z,11Z,14Z-eicosatetraenamide); O-2137, ((1R,3R)-1-[4-(1,1-Dimethylheptyl)- 
2,6-dimethoxyphenyl]-3-methylcyclohexanol); SR141716A, (5-(4-Chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-N-(1-piperidyl)pyrazole-3-carboxamide); SR144528, ((1S-endo)-5-(4-Chloro-3-
methyl-phenyl)-1-((4methylphenyl)methyl)-N-(1,3,3-trimethylbicyclo(2.2.1)hept-2-yl)-1H-pyrazole-3-
carboxamide) 
 
Adapted from Howlett et al., 2002
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experiments using antagonists, cells were exposed to SR141716A (SR1)(10-6M) or 
SR144528 (SR2)(10-6M) for 30 min prior to treatment with THC or CP55940 for 3h. 
Following vehicle or cannabinoid treatment, 100 μl of drug- or vehicle-treated cell 
suspension (106cells) were placed in the upper chamber of the transwell insert.  For 
assessment of chemotaxis (directed migration against a chemokine concentration 
gradient) the lower compartment was loaded (600μl) with medium containing murine 
RANTES (1 ng/ml; R&D Systems, Minneapolis, MN).  This concentration of RANTES 
was selected based on preliminary titration for a chemoattractant response that 
approximated a mid-point in the linear phase of the dose-response curve.  For assessment 
of chemokinesis (enhanced random migration to chemokine), RANTES (1 ng/ml) was 
included in both the top and bottom chambers to eliminate the chemoattractant 
concentration gradient.  In addition, for a select number of experiments, RANTES was 
eliminated from both chambers (Fig. 1).  The assembled migration plate chamber system 
was incubated (1-2 h) at 37oC in a 5%CO2 atmosphere.  To determine the number of cells 
that migrated to the bottom chamber, the upper chamber (i.e., polycarbonate filter) was 
removed and video still images (1mm2) in five random fields of each bottom chamber 
were captured using an Olympus CK2 inverted microscope (Opelco, Washington, DC) 
with an attached XV-GP230 digital video camera (Panasonic, Yokohama, Japan) 
interfaced to a Dell Dimension XPS1450 computer using Videum 100 hardware and 
Window NT software (Winnov, Sunnyvale, CA).  The number of cells migrating into the 
bottom compartment/transwell plate was manually enumerated and calculated as the sum 
of the five 1 mm2 fields and was represented as cells/mm2/well.  Each sample group was  
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Chemokinesis-
Enhanced Non-
directional 
Migration
ChemoattractantAssay medium
Transwell 
insert
Cells Cells
Cells + 
Chemoattractant
Chemoattractant
Random 
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Chemotaxis-
Directional 
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Figure 1- Transwell Migration Assay. Cells are loaded into transwell 
inserts and assessed for migration to the bottom well.  When the top and 
bottom wells contain assay medium only, any migration is random.  When 
the bottom well contains a chemoattractant, cell migration occurs in 
response to a concentration gradient.  This migration, chemotaxis, is 
compared to migration in which the chemoattractant substance is placed in 
both the top and bottom wells.  Under these conditiones, no concentration 
gradient exists and any migration that occurs as a response to exposure to a 
chemostimulus is called chemokinesis.  
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run in duplicate and each experiment was performed in triplicate.  Migration for each 
sample group was represented as the mean (±SD) of the total number of migrating cells 
counted in five fields of duplicate wells.  A greater than 2-fold increase in cell migration 
to the chemoattractant RANTES in the lower compartment as compared to that in the 
absence of RANTES in the lower compartment was indicative of a positive response. 
 
Immunoprecipitation of CCR5 
 Whole cell protein lysate (400 μg) in NP-40 lysis buffer containing protease 
inhibitors was precleared for 30 min using 0.25μg normal mouse control IgG (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) and 20 μl Protein A/G Plus Agarose (Santa Cruz 
Biotechnology).  Precleared protein lysates were incubated with 2 μg CCR5 antibody 
(CKR5 D6, Santa Cruz Biotechnology) for 2h at 4oC, followed by 12h incubation (4oC) 
with Protein A/G PlusAgarose.  The beads were collected by centrifugation (3000 RPM, 
4oC, 1 min) and washed four times in room temperature phosphate-buffered saline.  The 
precipitates were resuspended in 40 μl electrophoresis sample buffer, heated for 3 min at 
95oC, and resolved on a 10% SDS-polyacrylamide gel.   
 
Isolation of Cannabinoid Receptor DNA from Plasmid Contructs 
 In order to obtain CB1 DNA to serve as a positive control in Real Time RT-PCR 
assays, DH5α E.coli transfected with a pCD mammalian expression vector containing 
SKR6 (rat CB1 DNA sequence) from Dr. L. Matsuda (Medical University of South 
Carolina, Matsuda et al., 1990) were cultured in LB broth containing ampicillin (100 
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μg/ml).  The pCD-SKR6 plasmid was isolated using the Midi Prep Kit (Qiagen, Valencia, 
CA).  Following a restriction digest with EcoRI (Invitrogen) and BamHI (Invitrogen), the 
cut plasmid was subjected to agarose gel electrophoresis (0.8% agarose gel; OmniPure 
Agarose).  The 2.4 kb fragment containing the rat CB1 DNA sequence was cut from the 
agarose gel, isolated and purified using the QIAquick Gel Extraction Kit (Qiagen).  
Purified CB2 DNA from the pUC18 vector containing murine CB2 sequence from 
Dr. T. Bonner (NIMH, Bethesda, MD) was similarly obtained.  Both purified CB1 and 
CB2 DNA products were stored at –20oC in dH20 and the concentration determined using 
a BioPhotometer (Eppendorf, Westbury, NY).  Each product was sequenced at the MCV-
VCU Nucleic Acids Research Facility core lab using an Automated DNA sequencer.  
DNA samples were further analyzed by BLAST (nucleotide-nucleotide BLAST, NCBI, 
Bethesda, MD) to confirm sequence identity.   
   
Multiprobe Ribonuclease Protection Assay 
 Total RNA prepared from peritoneal macrophages using TRIzol reagent 
(Invitrogen, Carlsbad, CA) was redissolved after isopropanol precipitation directly in 1X 
hybridization buffer (BD Biosciences/PharMingen, San Diego, CA).  A Riboquant Multi-
probe Ribonuclease Protection Assay (RPA) was used to assess for levels of murine 
chemokine receptor mRNA (mcr-5 probe template set; BD Biosciences/PharMingen). 
The ribo-probes were labeled with 32P[UTP] (MP Biomedicals, Aurora, OH) to a specific 
activity of greater than 3,000Ci/mmol.  The isolated RNA samples then were hybridized 
with the probe overnight at 56oC and the protected fragments were resolved on a 6% 
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polyacrylamide gel containing 6M urea.  Imaging of the protected fragments was 
performed using a 445 SI Phosphorimager (Molecular Dynamics, Sunnyvale, CA).  The 
pixel intensity of each band was quantified using ImageQuant 4.1 software (Molecular 
Dynamics) and the amount of chemokine receptor mRNA was normalized for loading by 
dividing the pixel value for the chemokine receptor band by the sum of the pixel values 
for the mRNAs of the housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and a ribosomal protein, L32. 
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 Real–time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR), using 
SYBR Green for detection and primers for CB1 and CB2 and GAPDH, was used to assess 
for the presence of CB1 and CB2 mRNA, and for constitutively expressed GAPDH 
mRNA, respectively.  Total RNA from peritoneal macrophages was prepared using 
TRIzol reagent (Invitrogen) according the manufacturer’s instructions.  The RNA then 
was isolated by chloroform:isopropanol extraction and resuspended in 50 μl PCR grade 
water.  The isolated RNA was treated with RNase-free DNase I Amplification grade 
(Invitrogen) to remove residual genomic DNA.  The reverse transcription (RT) step was 
performed in a Bio-Rad iCycler (BioRad, Richmond, CA) using the SuperScript III First-
Strand Synthesis System (Invitrogen) that included random hexamers as primer to 
generate complementary DNA (cDNA).  SYBR Green real-time PCR was performed 
using the RT2 PCR Primer Set for mouse CB1 (Cnr 1: PPM04603A) or CB2 (Cnr 2: 
PPM04826A) and GAPDH (GAPDH:PPM02946A) as described by the manufacturer 
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(SuperArray Bioscience Corp., Frederick, MD).  Briefly, each 25 μl PCR mix consisted 
of 12.5 μl 2X RT2 Real-Time SYBR Green PCR Master Mix (SuperArray), 1.0 μl first 
strand cDNA template, and 1.0 μl RT2 PCR Primer Set brought to a final volume of 25 μl 
with DEPC-treated water.  Tubes containing the PCR mix were placed in a SmartCycler 
(Cepheid, Sunnyvale, CA) and PCR was performed using the following program: 95oC, 
15 min; 40 cycles of (95oC, 30 sec; 55oC, 30 sec; and 72oC, 30 sec).  The resulting PCR 
products were visualized by electrophoresis (100V) using 4% OmniPur Agarose PCR 
Plus (VWR, West Chester, PA) gel in 1X Tris-Borate-EDTA (TBE) buffer.  A pCD- and 
a pUC18-mCB2 plasmid template served as positive PCR controls for CB1 and CB2, 
respectively.  Using this approach, amplification products of 167 bp and 207 bp were 
generated for CB1 and CB2, respectively. 
 
Scanning Electron Microscopy 
 Transwell inserts containing polycarbonate filters with 8 μm pores were removed 
from the chemotaxis plates.  The top and bottom sides of the filter were washed gently to 
remove non-adherent cells and fixed with 2.5% gluteraldehyde.  Post-fixation with 
2%OsO4 was followed by dehydration in a graded series of alcohol washes (Pettit et al., 
1996).  The filters containing adherent macrophages were subjected to critical point 
drying, coated with gold and viewed with a JEOL scanning electron microscope (20kV).    
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SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Immunoblotting  
 Peritoneal macrophages were washed with room temperature PBS (2x) then 
incubated in NP-40 lysis buffer containing Protease Inhibitor Cocktail (100:1) (Sigma, St. 
Louis, MO; 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, 
leupeptin, aprotinin) for 30 min on ice.  The cell lysates were centrifuged at 10,000 x g 
for 15 min, at 40C.  The pellets then were discarded, the supernatants containing cellular 
proteins saved, and concentrations were determined by the Bradford assay.  Protein 
samples (40 μg/sample) were separated on a 12% polyacrylamide gel and transferred to a 
Transblot Transfer nitrocellulose membrane (BioRad, Hercules, CA).  The membranes 
were incubated individually with anti-CCR1, anti-CCR5, and anti-CB2 antibody.  The 
antibody to CCR1 (CKR1 H-52 rabbit polyclonal IgG, Santa Cruz Biotechnology) was 
directed against the extracellular amino terminus whereas the antibody to CCR5 (CKR5 
D-19 mouse monoclonal IgG, Santa Cruz Biotechnology) was directed against the 
carboxy terminal domain.  The antibody to CB2 (CB2 M15 goat polyclonal IgG, Santa 
Cruz Biotechnology) was raised against peptide mapping of the C terminus of mouse 
CB2. 
 
Statistical Analysis 
 Analysis of variance (ANOVA) was performed using Dunnett’s test and was 
followed by a Student’s t-test to allow for comparison of each sample to the vehicle.  
Comparisons between treatment groups were performed using Bonferroni’s t test.    
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Results 
Murine Thioglycollate-Elicited Peritoneal Macrophages Express the Chemokine 
Receptors CCR1 and CCR5 and the Cannabinoid Receptor CB2
 RANTES binds to the chemokine receptors CCR1, CCR3, and CCR5 (Murphy, 
2002; Bajetto et al., 2002; Charo et al., 2006).  Thus, in order to determine the CC 
chemokine receptor gene expression profile of (B6C3)F1 and C57BL/6 murine 
thioglycollate-elicited peritoneal macrophages, a multiprobe RNase Protection assay was 
employed.  Using a template set for CC chemokine receptors, it was demonstrated that the 
predominant chemokine receptor mRNAs detected for (B6C3)F1 mice were those for 
CCR1, CCR2 and CCR5 (Fig. 2).  C57BL/6 mice contained approximately equal levels of 
mRNA for CCR1 and CCR5 but, in contrast to (B6C3)F1 mice, contained low levels of 
mRNA for CCR2.  Because RANTES is a major agonist for CCR1 and CCR5, but not 
CCR2, the presence of protein for the former two receptors also was determined (Fig. 3). 
Consistent with the mRNA data, approximately equivalent levels of protein for CCR1 and 
CCR5 were detected in thioglycollate-elicited macrophages of (B6C3)F1 and C57BL/6 
mice.   
 SYBR Green RT-PCR was employed to assess for the presence of CB2 mRNA in 
peritoneal macrophages from (B6C3)F1  and C57BL/6 mice.  Prior to performing PCR, 
CB1 and CB2 cDNA was isolated from plasmid preparations of DH5α E. coli that had 
been transfected with mammalian expression vectors containing CB1 and CB2 DNA 
sequences (pCD-rSKR6 and pUC18-mCB2, respectively) for use as positive controls in 
Real-time RT-PCR.  The isolated plasmids were digested with restriction enzymes EcoRI  
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Figure 2 – CCR1 and CCR5 mRNA Are Expressed by Peritoneal 
Macrophages.  RNase Protection Assay demonstrated that peritoneal 
macrophages express predominantly CCR1 and CCR5, with low levels of 
CCR2 expression. P- Undigested probe, Y- yeast control (-), M- mouse 
control (+), 1-(B6C3)F1 peritoneal macrophages, 2- C57BL/6 peritoneal 
macrophages, 3- CB2 -/- BM cell line (Raborn et al., 2007). 
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B6 C57                B6       C57 B B CC
Figure 3– Peritoneal Macrophages Express CCR1, CCR5, and CB2 at the 
Protein Level.  Whole cell lysates from (B6C3)F1 and C57BL6 murine 
peritonal macrophages were separated by SDS-PAGE followed by Western 
immunoblot analysis with antibodies to CCR1, CCR5, and Actin. B6- 
(B6C3)F1, C57- C57BL/6    
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and BamHI to release cannabinoid receptor DNA sequences.  The digests were subjected 
to agarose gel electrophoresis and CB1 and CB2 DNA was extracted from the gel and 
purified (Fig. 4)(CB1 fragment 2.4kb, CB2 fragment 1.3kb).  A 207 bp amplicon, 
consistent with the fragment size predicted for the CB2, was detected from total RNA of 
peritoneal macrophages (Fig. 5).  Western immunoblot analysis using a murine CB2 
domain-specific antibody confirmed the presence of CB2 in murine peritoneal 
macrophages at the protein level (Fig. 3).  Furthermore, using SYBR Green RT-PCR 
(Fig. 5) and Western immunoblot analysis (Data not shown) the absence of CB1 mRNA 
or protein expression in thioglycollate-elicited peritoneal macrophages from (B6C3)F1  
and C57BL/6 mice was demonstrated.   
 
Treatment with THC in vivo Results in Inhibition of the Chemotactic Response of Murine 
Peritoneal Macrophages to RANTES in vitro. 
 (B6C3)F1 mice were inoculated with thioglycollate and 5 days later were 
administered a single intraperitoneal injection of vehicle (ethanol:emulphor:saline, 
1:1:18) or THC (25 mg/kg or 50 mg/kg).  Peritoneal macrophages were harvested 24h 
later and were subjected to migration assay.  In vivo administration of 25 mg/kg or 50 
mg/kg THC resulted in a significant and greater than 50% inhibition of cell migration in 
response to RANTES as compared to that observed for cells of mice receiving vehicle 
(Fig. 6).  No significant differences in migration were obtained between vehicle and drug 
treated cells when RANTES was placed in both the top and bottom compartments to  
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Figure 4- Generation of Real-time RT-PCR CB1 and CB2 positive control 
DNA.  pUC18-mCB2 was digested with EcoR1 and BamH1 to release 
mCB2 DNA (1.3 kb).  B. pCD-sKR6 (rCB1)was digested with EcoR1 and 
BamHI to release 2.4 kb fragment of rCB1 DNA.   
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Figure 5- Cannabinoid Receptor mRNA Expression by Peritoneal 
Macrophages.  Real-time RT-PCR demonstrated that peritoneal macrophages 
express primarily CB2 mRNA.  CB1 and CB2 DNA as well as GAPDH were 
used as positive controls.   
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Figure 6- Treatment in vivo with THC Results in Inhibition of the Chemotactic 
Response to RANTES.  (B6C3)F1 mice were injected intraperitoneally with 10% 
thioglycollate to elicit macrophages. Five days later, the mice were injected 
intraperitoneally with vehicle (VEH) (1:1:18, ethanol:emulphor:saline) or THC (25 
mg/kg or 50 mg/kg). Migration of macrophages to 1ng/ml RANTES was assessed in 
vitro using transwell tissue culture inserts. Results are presented as the mean ± SD. 
For RANTES placed only in the bottom chamber, SD was compared with that of 
vehicle-treated macrophages exposed to RANTES in the bottom chamber. For 
RANTES placed in both chambers (shaded bars), SD was compared with that of 
vehicle-treated macrophages exposed to RANTES in both chambers. When RANTES 
was added only to the bottom compartment, THC as compared to the vehicle control 
exerted a major inhibitory effect on cell migration to the bottom compartment. When 
RANTES was added to both the upper and lower compartments to eliminate the 
chemoattractant concentration gradient, THC as compared to the vehicle control did 
not result in significant inhibition of cell migration to the bottom well. These results 
indicate that THC inhibits directed migration (i.e., chemotaxis) to a RANTES 
concentration gradient rather enhancement of random movement (i.e., chemokinesis) 
to RANTES. **p<0.01. 
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eliminate the RANTES concentration gradient.  These results are consistent with THC as 
exerting an inhibitory effect on the macrophage chemotactic response to RANTES. 
 
Treatment with THC and CP55940 in vitro Results in Inhibition of the Chemotactic 
Response of Murine Peritoneal Macrophages to RANTES 
 In order to determine whether THC exerted a direct effect on macrophages, in 
vitro exposure experiments were performed. THC treatment of (B6C3)F1 murine 
peritoneal macrophages in vitro resulted in a significant inhibition of the chemotactic 
response to RANTES (Fig. 7).  Cells treated with vehicle exhibited a minimal level of 
migration (i.e., approximately 1,600 cells/mm2/well) to the bottom compartment in the 
absence of RANTES.  In contrast, when RANTES was added to the bottom compartment 
to establish a chemokine concentration gradient, a nearly five-fold increase (i.e., in excess 
of 5,000 cells/mm2/well) was obtained for macrophages treated with vehicle.  Treatment 
of macrophages with THC (10-6M – 10-12M) resulted in a significant inhibition of 
migration in response to RANTES.  THC, at a concentration as low as 10-12M, exerted a 
major inhibitory effect on cell migration, with numbers of cells in the bottom 
compartment approximating those for cells treated with vehicle and not exposed to 
RANTES.  Again, the inhibitory effect of THC on macrophage migration was at the level 
of chemotaxis rather than chemokinesis.  When RANTES was added to both the upper 
and lower compartments to eliminate the chemoattractant concentration gradient to allow 
for assessment of random migration to chemokine, approximately 1,000 cells/mm2/well 
were obtained for peritoneal macrophages treated with vehicle.  Treatment of these cells  
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Figure 7 - Treatment in vitro with THC Results in Inhibition of the Chemotactic 
Response to RANTES. A.  Migration of peritoneal macrophages to 1ng/ml 
RANTES was assessed following in vitro treatment (3h) with THC (10-6  to 10-12  
M) or vehicle (VEH) (0.01% ethanol).  Treatment with the partial agonist THC 
resulted in inhibition of chemotaxis. Results are presented as the mean  ± SD. For 
RANTES placed only in the bottom chamber, SD was compared with that of 
vehicle-treated macrophages exposed to RANTES in the bottom chamber. For 
RANTES placed in both chambers (shaded bars), SD was compared with that of 
vehicle-treated macrophages exposed to RANTES in both chambers. *p<0.05, 
**p<0.01, ***p<0.001.  B. Results presented as Percent Inhibition of migration.   
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with 10-8M or 10-11M THC did not result in significant inhibition of this random 
movement. Rather, a slight augmentation in random migration to the bottom compartment 
was recorded.  
 Experiments performed with THC were replicated using CP55940, a high efficacy 
agonist at CB1 and CB2 (Fig. 8).  Again, a minimal level in cell migration was observed 
for control wells.  Approximately 1,500 cells/mm2/well were recorded when vehicle-
treated cells were placed in the top compartment in the absence of RANTES in the 
bottom compartment.  An approximate four-fold increase in the number of peritoneal 
macrophages treated with vehicle was obtained when RANTES was placed in the bottom 
compartment to establish a chemoattractant gradient.  Treatment of cells with CP55940 
(10-6M – 10-12M) resulted in a significant concentration-related decrease in migration in 
response to RANTES.  A greater than 50% inhibition in migration was obtained for cells 
treated with CP55940 at 10-6M – 10-9M as compared to vehicle control.  CP55940 as 
compared to vehicle did not affect macrophage migration when RANTES was placed 
both in the top and bottom compartments to eliminate the chemoattractant gradient, 
indicating that the effect of CP55940 on migration was at the level of chemotaxis rather 
than chemokinesis.  
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Figure 8- Treatment in vitro with CP55940 Results in Inhibition of the Chemotactic 
Response to RANTES. A.  Migration of peritoneal macrophages to 1ng/ml RANTES was 
assessed following in vitro treatment (3h) with CP55940 (CP) (10-6 to 10-12  M) or vehicle 
(VEH) (0.01% ethanol). Treatment with the full agonist CP55940 resulted in a robust 
dose-related inhibition of chemotaxis to RANTES. Results are presented as the mean  ± 
SD. For RANTES placed only in the bottom chamber, SD was compared with that of 
vehicle-treated macrophages exposed to RANTES in the bottom chamber. For RANTES 
placed in both chambers (shaded bars), SD was compared with that of vehicle-treated 
macrophages exposed to RANTES in both chambers. *p<0.05, **p<0.01. B. Results 
presented as Percent Inhibition of Migration.   
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The CB2-selective Ligand O-2137 Exerts a Robust Inhibitory Effect on the Murine 
Peritoneal Macrophage Chemotactic Response to RANTES 
 The concentration-related inhibitory effect most evident using CP55940 on the 
chemotactic response of murine peritoneal macrophages to RANTES implicated a role 
for a cannabinoid receptor in this process.  In order to obtain insight as to the cannabinoid 
receptor linked to the inhibitory effect, macrophages from (B6C3)F1 mice were treated 
with compounds exhibiting selective high affinity binding to the CB1 or the CB2 prior to 
assessment of the chemotactic response to RANTES.  Treatment of macrophages with the 
highly selective CB2 ligand O-2137 resulted in a profound and significant concentration-
related inhibition in the chemotactic response to RANTES (Fig. 9).  For drug 
concentrations of 10-6M – 10-8M, a greater than 50% inhibition, as compared to vehicle 
control, was observed.  In contrast, the CB1 specific ligand ACEA (10-6M – 10-12M) 
exerted a minimal inhibitory effect on the peritoneal macrophage chemotactic response to 
RANTES (Fig. 10).  
The CB2-specific Antagonist SR144528 Reverses the Inhibitory Effect of CP55940 on the 
Murine Peritoneal Macrophage Chemotactic Response to RANTES 
In order to confirm the data indicating that activation of the CB B2 with a 
cannabinoid receptor selective ligand exerted a major inhibitory effect on the chemotactic 
response to RANTES, cannabinoid receptor agonist-antagonist experiments were 
performed.  For these experiments, the CB1 or CB2 antagonist was used at a concentration 
of 10 M.  Treatment of (B-6 6C3)F1 murine peritoneal macrophages with the CB2-specific  
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B.
Figure 9- Effect of the CB2-selective Ligand on the Chemotactic Response to 
RANTES. A.  Treatment (3h) with the CB2-selective ligand O-2137 resulted in a 
robust and significant inhibition of chemotaxis. Results are presented as the mean  ± 
SD. For RANTES placed only in the bottom chamber, SD was compared with that 
of vehicle-treated macrophages exposed to RANTES in the bottom chamber. For 
RANTES placed in both chambers (shaded bars), SD was compared with that of 
vehicle (VEH)-treated macrophages exposed to RANTES in both chambers. 
*p<0.05, **p<0.01. B. Results presented as Percent Inhibition of migration.   
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Figure 10- Effect of the CB1-selective Ligand on the Chemotactic Response to RANTES. 
A.  Treatment with the CB1-selective ligand ACEA had a minimal effect on RANTES-
induced migration of peritoneal macrophages. Results are presented as the mean  ± SD. 
For RANTES placed only in the bottom chamber, SD was compared with that of vehicle 
(VEH)-treated macrophages exposed to RANTES in the bottom chamber. For RANTES 
placed in both chambers (shaded bars), SD was compared with that of vehicle-treated 
macrophages exposed to RANTES in both chambers. *p<0.05. B.  Results presented as 
Percent Inhibition of migration. 
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antagonist SR144528 (SR2) alone had no major effect on the chemotactic response to 
RANTES.  At equimolar concentrations (i.e., 10-6M) of antagonist and agonist, CP55940 
inhibited macrophage chemotaxis to RANTES.  However, at lower concentrations of 
CP55940 (10-7M – 10-11M), the inhibitory effect of the agonist was reversed by the CBB2 
antagonist SR144528 (Fig. 12).  These results were in direct contrast to those obtained 
when the CB1 antagonist SR141716A (SR1) was used (Fig. 11).  Treatment with SR1 
(10 M – 10 M) did not block the inhibitory effect of CP55940.  -6 -12
 
THC Does Not Inhibit the Chemotactic Response to RANTES of Peritoneal Macrophages 
from CB2 Knockout Mice  
 To confirm the pharmacological data implicative of a functional linkage of the 
CB2 to cannabinoid-mediated inhibition of macrophage chemotaxis to RANTES, 
experiments were performed using thioglycollate-elicited peritoneal macrophages from 
C57BL/6 CB2 knockout mice.  THC (10-5M – 10-9M) had no significant effect on either 
the chemotactic or chemokinetic response of macrophages from the knockout mice (Fig. 
13).  Since these CB2 null animals were generated on a C57BL/6 genetic background, 
replicate migration experiments were performed using thioglycollate-elicited peritoneal 
macrophages from their C57BL/6 CB2 (+/+) wild-type counterparts.  Consistent with the 
data obtained using (B6C3)F1 mice, THC exerted a concentration-related inhibition of the 
chemotactic response of peritoneal macrophages to RANTES (Fig. 14).   
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Figure 11- Effect of CB1 Cannabinoid Receptor Antagonist on Chemotaxis to 
RANTES. Treatment with the CB1 antagonist SR141716A (SR1)(10-
6 M) did not 
block CP55940 (CP)-mediated inhibition of chemotaxis. Macrophages were 
treated (30 min) with antagonist prior to treatment (3h) with cannabinoid. Results 
are presented as the mean ± SD. For RANTES placed only in the bottom chamber, 
SD was compared with that of vehicle (VEH)-treated macrophages exposed to 
RANTES in the bottom chamber. For RANTES placed in both chambers (shaded 
bars), SD was compared with that of vehicle-treated macrophages exposed to 
RANTES in both chambers. *p<0.05, **p<0.01.  
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Figure 12- Effect of CB2 Cannabinoid Receptor Antagonist on Chemotaxis to 
RANTES.  The CP55940 (CP)-mediated inhibition of chemotaxis was reversed by  
SR144528 (SR2)(10-6  M). Macrophages were treated (30 min) with antagonist prior 
to treatment (3h) with cannabinoid. Results are presented as the mean ± SD. For 
RANTES placed only in the bottom chamber, SD was compared with that of vehicle 
(VEH)-treated macrophages exposed to RANTES in the bottom chamber. For 
RANTES placed in both chambers (shaded bars), SD was compared with that of 
vehicle-treated macrophages exposed to RANTES in both chambers. *p<0.05, 
**p<0.01, ***p<0.001.  
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Figure 13- Effect of THC on the Chemotactic Response of Peritoneal 
Macrophages from CB2 Knockout Mice to RANTES. In vitro THC treatment (3h) 
did not have a significant effect on RANTES-induced migration by peritoneal 
macrophages from CB2 receptor knockout mice. Results are presented as the mean 
± SD. For RANTES placed only in the bottom chamber, SD was compared with 
that of vehicle (VEH)-treated macrophages exposed to RANTES in the bottom  
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Figure 14- Effect of THC on the Chemotactic Response of Peritoneal Macrophages from 
the Wild-type Counterpart. THC treatment (3h) resulted in a concentration-related 
inhibition of the chemotactic response of peritoneal macrophages to RANTES from the 
C57BL/6 CB2 (+/+) wild-type counterpart. Results are presented as the mean ± SD. For 
RANTES placed only in the bottom chamber, SD was compared with that of vehicle 
(VEH)-treated macrophages exposed to RANTES in the bottom. *p<0.05, **p< 0.01, 
***p<0.001 
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THC Alters Functional Morphology of Murine Peritoneal Macrophages Undergoing 
Chemotaxis to RANTES 
 Transwell chemotaxis assays revealed that THC inhibits peritoneal macrophage 
migration to RANTES.  Scanning electron microscopy analysis of the transwell 
membranes demonstrated that cells treated with THC exhibited altered morphology and 
were apparently impaired in their ability to migrate through the pores into the bottom 
chamber containing the chemoattractant.  Vehicle-treated (0.01% Ethanol) peritoneal 
macrophages exposed to RANTES exhibited characteristics indicative of cell migration 
including cell membrane ruffling and lobose cellular extensions (pseudopodia formation) 
(Fig. 15).  Additionally, numerous vehicle-treated macrophages were found in or in close 
proximity to the membrane pores with pseudopodia extending toward the pore (Fig. 15).  
In contrast, peritoneal macrophages treated with THC were rounded in appearance, with 
the absence of cellular extensions.  Few THC-treated macrophages were observed close 
to or in filter pores.  
 
THC Does Not Alter mRNA Levels of CC Chemokine Receptors in Thioglycollate-Elicited 
Murine Peritoneal Macrophages 
 Chemotaxis to RANTES results from a complex series of signal transductional 
activities following ligation of the chemokine to its cognate G protein-coupled receptor. 
THC treatment of macrophages could affect activation of chemokine receptors and alter 
their expression and/or compartmentalization.  Thus, in order to obtain initial insight as to  
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Vehicle             Vehicle             THC (10-6M) 
Figure 15– THC Alters the Morphology of Peritoneal Macrophages 
Migrating to RANTES.  Scanning electron microscopy of transwell inserts 
of peritoneal macrophages treated with Vehicle (0.01% Ethanol) migrating 
towards 1ng/ml RANTES (note multiple cellular projections).  Cells 
treated with THC are rounded in appearance and do not seem to be 
migrating toward RANTES.  Scale bars 1, 10, and 10 mm left to right.   
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the mode of action through which THC treatment results in inhibition of chemotaxis, 
experiments were performed to assess for levels CC chemokine mRNA in peritoneal 
macrophages.  THC (10-6M -10-12M) treatment of (B6C3)F1 peritoneal macrophages (3h) 
had no major effect on total mRNA levels of CCR1, CCR2 or CCR5 (Fig. 16). 
Additionally, treatment with a battery of cannabinoid receptor agonists and antagonists 
(THC, CP55940, SR1, and SR2 at 10-6M) also had no major effect on chemokine 
receptor mRNA levels (Fig. 17).  Chemokine receptor mRNA levels also were assessed 
for peritoneal macrophages exposed to THC in vivo (50mg/kg THC for 24h prior to 
harvest of peritoneal macrophages).  Consistent with results obtained in vitro, THC 
treatment had no major effect on the expression of CCR1, CCR2, or CCR5 at the level of 
total mRNA (Data not shown).  Similarly, at this concentration range THC had no major 
effect on total mRNA levels of CB2 (Data not shown).   
Heterologous Desensitization of Chemokine Receptors by Cannabinoids 
 G-protein coupled receptors display reduced responsiveness with prolonged or 
repeated agonist stimulation, a process known as receptor desensitization.  Upon 
phosphorylation by G-protein receptor kinases (GRKs) receptor internalization and 
recycling is initiated.  In cell types expressing numerous classes of G-protein coupled 
receptors, signaling through one class of GPCR has been shown to trans-deactivate other 
receptor types through heterologous desensitization.  It is therefore possible that 
cannabinoid treatment could affect chemokine receptor function, resulting in reduced 
responsiveness to chemokines. In order to obtain insight regarding whether cannabinoid  
   
    
  
46
 
CCR1
CCR5
CCR2
L32
GAPDH
VEH   - 6   - 7    - 8    - 9   - 10  - 11 - 12
THC (log10 M)
Figure 16- Effect of THC on Levels of CC Chemokine Receptor mRNA.  
Multiprobe ribonuclease protection assay demonstrated that THC (10-6 M – 
10-12 M) treatment (3h) had no major effect on levels of CCR1, CCR2, and 
CCR5 mRNA in thioglycollate-elicited (B6C3)F1 murine peritoneal 
macrophages.  
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Figure 17- Effect of Select Cannabinoids on Levels f CC Chemokine 
Receptor mRNA.  Multiprobe ribonuclease protection assay demonstrated 
that THC, CP55940, SR1, or SR2  (10-6 M) treatment (3h) had no major 
effect on levels of CCR1, CCR2, and CCR5 mRNA in thioglycollate-
elicited (B6C3)F1 murine peritoneal macrophages. 
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 treatment caused heterologous desensitization of chemokine receptors, experiments were 
performed to assess levels of CCR5 phosphorylation following stimulation with 
RANTES or CP55940.  Treatment of peritoneal macrophages with cognate ligand 
RANTES (1ng/ml) (1h) resulted in increased CCR5 phosphorylation compared to vehicle 
(Fig. 18).  CP55940 treatment also enhanced CCR5 phosphorylation, though not to the 
same extent as the cognate agonist, indicating that heterologous desensitization of 
chemokine receptors by cannabinoids may be occurring.   
 
Endogenous Cannabinoid 2-Arachidonylglycerol (2-AG) Induces Murine Peritoneal 
Macrophage Migration      
 Numerous groups have reported that select cannabinoids are capable of inducing 
migration in a variety of immune cell types including microglia and cell lines of myeloid 
origin (Walter et al., 2003; Jordá et al., 2002; Kishimoto et al., 2005); however, to date 
there have been no published reports specifically utilizing primary macrophages from the 
periphery.  To address this, experiments were performed to assess the ability of the 
endogenous cannabinoid, 2-AG (1 nM to 5 μM) to induce peritoneal macrophage 
migration.  Maximal macrophage migration was observed using 1μM 2-AG (Fig. 19), 
consistent with data obtained using other cell types. 
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Figure 18– Stimulation with RANTES and Cannabinoid Receptor 
Agonist CP55940 Induces CCR5 Phosphorylation.  Peritoneal 
macrophages were treated for 1h with vehicle, RANTES (1ng/ml), or 
CP55940 (10-6 M) and harvested for protein.  Whole cell protein lysates 
of peritoneal macrophages were precleared with normal mouse IgG.  A 
CCR5 antibody was used to immunoprecipitate CCR5 from the 
precleared protein lysate. Following SDS-PAGE, the immunoblot (A.) 
was probed with an antiphosphoserine antibody to detect CCR5 
phosphorylation.  B. Densitometric analysis of CCR5 phosphorylation.  
V-vehicle, R- RANTES, CP-CP55940.    
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Figure 19 – The Endogenous Cannabinoid 2-AG Induces Peritoneal Macrophage 
Chemotaxis.  Transwell chemotaxis assay was utilized to assess chemoattractant 
properties of 2-AG (4h) (0.01-5 μΜ).  Results are presented as mean ± SD.   
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Treatment with THC Inhibits Murine Peritoneal Macrophage Migration to 2-AG 
 Further experiments were performed to address whether treatment with THC 
could inhibit peritoneal macrophage chemotaxis to 2-AG.  Treatment of macrophages 
with THC (10-6M – 10-8M) resulted in a significant inhibition of migration in response to 
2-AG (Fig 20). 
 
Migration of Murine Peritoneal Macrophages to Amoebic Conditioned Medium 
 In studies using an in vivo murine model of Acanthamoeba infection, Marciano-
Cabral and Cabral (2003) demonstrated that macrophage-like cells are the primary 
immune cell component in granulomas, which are formed in response to amoebic 
infection.  It has been proposed that these granulomas may serve to sequester the ameba, 
thereby preventing further dissemination (Fig. 21).  Additionally, exposure to THC 
exacerbated Acanthamoeba infection, characterized by increased mortality and numbers 
of amoeba present in brain sections, as well as the absence of granuloma formation (Fig. 
21).  Acathamoeba infection notably results in dramatic and extensive tissue damage, 
which occurs through a combination of direct contact and the secretion of numerous lytic 
enzymes (Table 4).  Experiments, therefore, were performed to assess peritoneal 
macrophage migration to amebic conditioned medium (0-72 μg) obtained from cultures 
incubated with Acanthamoeba culbertsoni (AcCM) and Acanthamoeba (JH1) (JH1CM), 
a clinical isolate containing intracellular bacteria.  Amebic conditioned medium from A. 
culbertsoni (Fig. 22) and JH1 isolate (similar results, data not shown) induced  
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Figure 20– THC Inhibits Peritoneal Macrophage Chemotaxis to 2-AG.  
Peritoneal macrophages were treated with THC (10-6 -10-12 M) for 3 h and then 
assessed for chemotaxis to 1 μM 2-AG (2h). VEH- vehicle (0.01% ethanol).  
*p<0.05, **p<0.01.  
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A.  B. 
Figure 21– A. Hematoxylin and Eosin (H&E) Stained Section of Paraffin-
embedded Brain Tissue Demonstrating Granuloma Formation in Acanthamoeba 
infection. B.  Sections of paraffin-embedded brain tissue demonstrating granuloma 
formation in Acanthamoeba infection. Top panel- Vehicle treated mouse.  Bottom 
panel- THC-treated mouse. Images courtesy of Marciano-Cabral and Cabral 2003 
and Cabral et al., 2007.   
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Table 4- Acanthamoeba Secreted Factors 
 
Product        Action     Reference 
 
Serine Protease (33 kD)      degrades IgG and IgA  Kong et al., 2000 
 
Lytic enzymes        involved in invasion  Moore et al., 1991 
         Alfieri et al., 2000 
 
Serine and cysteine       markers for pathogenicity             Hadas and Mazur 
proteinases        1993 
 
Serine, cysteine and        degrade type I collagen  Mitro et al., 1994 
metalloproteinases        
 
Serine protease (42kD)      degrades collagen   Cho et al., 2000 
 
Serine protease (33kD)      implicated in virulence  Kim et al., 2006 
 
Serine protease (85,130kD)      degrades types I and III collagen Sissons et al., 2006 
         elastin, plasminogen, casein, 
         and hemoglobin 
 
Metalloprotease (150kD)      degrades types I and III collagen   
         elastin, plasminogen, casein, 
         and hemoglobin   
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Figure 22 – Peritoneal Macrophages Migrate in Response to Amoebic 
Conditioned Medium.  Transwell migration assays (2h) were performed 
to assess peritoneal macrophage migration to Acanthamoeba conditioned 
medium (Acanthamoeba culbertsoni- 0-72 μg).      
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macrophage migration with a greater than 2-fold increase observed at concentrations of 
conditioned medium as low as 36μg.     
 
Treatment with THC Inhibits the Chemotactic Response of Murine Peritoneal 
Macrophages to Amoebic Conditioned Medium 
 In order to determine whether THC exerted a direct effect on macrophage 
migration to amebic conditioned medium, in vitro exposure experiments were performed. 
A minimal level of cell migration was observed for control wells.  An approximate three-
fold increase in the number of peritoneal macrophages treated with vehicle was obtained 
when amoebic conditioned medium was placed in the bottom compartment to establish a 
chemoattractant gradient.  Treatment of cells with THC (10-6-10-10M) resulted in a 
significant concentration-related decrease in migration in response to Acanthamoeba 
(JH1) conditioned medium (JH1CM; 36μg) (Fig. 23).  Similarly, treatment of cells with 
THC (10-6-10-11M) resulted in a significant concentration-related decrease in migration in 
response to Acanthamoeba culbertsoni conditioned medium (AcCM; 36μg) (Fig. 24).   
 
Treatment with THC in vivo Results in Inhibition of Murine Peritoneal Macrophage 
Migration to Amoebic Conditioned Medium in vitro 
 (B6C3)F1 mice were inoculated with vehicle (ethanol:emulphor:saline, 1:1:18) or 
THC (5, 10, 25 or 50 mg/kg) (one injection per day for 4 days).  On the last day of 
injections, thioglycollate was administered and 5 days later peritoneal macrophages were 
harvested.  Migration assays were performed to assess the effect of in vivo THC exposure  
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Figure 23– THC Inhibits Peritoneal Macrophage Chemotaxis to Acanthamoeba
Condtioned Medium.   Peritoneal macrophages were treated with THC (10-6- 
10-12 M) for 3h and then assessed for migration to 36 μg Acanthamoeba (JH1) 
conditioned medium (1h).  *p<0.05, ***p<0.001. VEH- vehicle (0.01% 
ethanol). 
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Figure 24– THC Inhibits Peritoneal Macrophage Chemotaxis to 
Acanthamoeba Conditioned Medium. Peritoneal macrophages were 
treated with THC (10-6- 10-12 M) for 3h then assessed for migration to 36 
μg Acanthamoeba culbertsoni conditioned medium (AcCM) for 1h. 
Results are presented as mean ± SD. **p<0.01, ***p<0.001. VEH- 
vehicle (0.01% ethanol).  
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on in vitro migration to amoebic conditioned medium.  In vivo administration of 10 
mg/kg or 25 mg/kg THC resulted in a significant and greater than 50% inhibition of cell 
migration to Acanthamoeba culbertsoni conditioned medium (AcCM; 36μg) (Fig. 25).   
 
Treatment with CP55940 Inhibits the Chemotactic Response of Murine Peritoneal 
Macrophages to Amoebic Conditioned Medium 
 Experiments performed with THC were replicated using CP55940, a high efficacy 
agonist at CB1 and CB2.  Treatment of cells with CP55940 (10-6-10-10 and 10-12 M) 
resulted in a significant concentration-related decrease in chemotaxis in response to 
Acanthamoeba (JH1) conditioned medium (JH1CM; 36μg) (Fig. 26).  Greater than 50% 
inhibition of cell migration to amebic conditioned medium was observed with CP55940 
treatment at concentrations of 10-6-10-10M compared to vehicle-treated macrophages.     
 
The CB2-selective Ligand O-2137 Exerts a Robust Inhibitory Effect on the Murine 
Peritoneal Macrophage Chemotactic Response to Amoebic Conditioned Medium 
 In order to determine whether a cannabinoid receptor was linked to the observed 
inhibitory effect, macrophages from (BB6C3)F1 mice were treated with compounds 
exhibiting selective high affinity binding to the CB1 or the CB2 prior to assessment of the 
chemotactic response to amoebic conditioned medium.  Treatment of macrophages with  
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Figure 25- In vivo Exposure to THC Inhibits Peritoneal Macrophage 
Chemotaxis to Acanthamoeba Conditioned Medium. (B6C3)F1 mice were 
inoculated with vehicle (VEH) (ethanol:emulphor:saline, 1:1:18) or THC (5, 
10, 25 or 50 mg/kg) (one injection per day for 4 days) and peritoneal 
macrophages harvested 5 days later.  Migration to Acanthamoeba culbertsoni 
conditioned medium (AcCM; 36μg) was assessed.  Results are presented as 
mean ± SD. *p<0.05. 
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Figure 26– CP55940 Inhibits Peritoneal Macrophage Chemotaxis to 
Acanthamoeba Conditioned Medium. Peritoneal macrophages were treated 
with CP55940 (CP) (10-6- 10-12 M) for 3h then assessed for migration to 36 
μg Acanthamoeba (JH1) conditioned medium (JH1CM) for 1h. Results are 
presented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001.  VEH- vehicle 
(0.01% ethanol). 
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the highly selective CB2 ligand O-2137 resulted in a profound and significant 
concentration-related inhibition in the chemotactic response to Acanthamoeba (JH1) 
conditioned medium (JH1CM; 36 μg) (Fig. 27).  For drug concentrations of 10-6M – 10-
8M, a greater than 50% inhibition, as compared to vehicle control, was observed.  In 
contrast, the CB1 specific ligand ACEA (10-6M – 10-12M) had no inhibitory effect on the 
peritoneal macrophage chemotactic response to Acanthamoeba (JH1) conditioned 
medium (JH1CM; 36 μg) (Fig. 28).  
 
CB2-specific Antagonist SR144528 (SR2) Reverses the Inhibitory Effect of CP55940 on 
the Murine Peritoneal Macrophage Chemotactic Response to Amoebic Conditioned 
Medium 
 Cannabinoid receptor agonist-antagonist experiments were performed to further 
confirm the previous data indicating that activation of the CB2 with a cannabinoid 
receptor selective ligand exerted a major inhibitory effect on the chemotactic response to 
amoebic conditioned medium.  For these experiments, the CB2 antagonist SR144528 
(SR2) was used at a concentration of 10-6M.  Treatment of (B6C3)F1 murine peritoneal 
macrophages with the CBB2-specific antagonist SR2 alone had no significant effect on the 
chemotactic response to Acanthamoeba (JH1) conditioned medium (JH1CM; 54 μg), as 
there was no significant difference in migration to JH1CM by SR2- or vehicle-treated 
cells (Fig. 29).  At equimolar concentrations (i.e., 10 M) of antagonist and agonist, -6
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Figure 27 – The CB2 Selective Agonist O-2137 Inhibits Peritoneal Macrophage 
Chemotaxis to Acanthamoeba Conditioned Medium. Peritoneal macrophages 
were treated with O-2137 (10-6- 10-12 M) for 3h then assessed for migration to 36 
μg Acanthamoeba (JH1) conditioned medium (JH1CM) for 1h. Results are 
presented as mean ± SD. *p<0.05, **p<0.01.  VEH- vehicle (0.01% ethanol). 
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Figure 28 – The CB1 Selective Agonist ACEA Has No Effect on Peritoneal 
Macrophage Migration to Acanthamoeba Conditioned Medium.  Peritoneal 
macrophages were treated with ACEA (10-6- 10-12 M) for 3h then assessed 
for migration to 36 μg Acanthamoeba (JH1) conditioned medium (JH1CM) 
for 1h. Results are presented as mean ± SD. VEH- vehicle (0.01% ethanol). 
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Figure 29- Effect of Cannabinoid Receptor Antagonist on Chemotaxis to 
Acanthamoeba Conditioned Medium.  The CP55940 (CP)-mediated inhibition of 
chemotaxis was reversed by the CB2 antagonist (SR2) SR144528 (10
-6 M). 
Macrophages were treated (30 min) with antagonist prior to treatment (3h) with 
cannabinoid and assessed for migration to 54 μg Acanthamoeba (JH1) conditioned 
medium (JH1CM)(1h).  Results are presented as the mean ± SD. For cannabinoid-
treated cells exposed to amoeba conditioned medium placed only in the bottom 
chamber, SD was compared with that of vehicle-treated macrophages exposed to 
conditioned medium in the bottom chamber. For cannabinoid-treated cells exposed 
to conditioned medium placed in both chambers (shaded bars), SD was compared 
with that of vehicle (VEH)-treated macrophages exposed to conditioned medium in 
both chambers.  ***p<0.001.  
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CP55940 inhibited macrophage migration to JH1CM.  Additionally, referencing Fig. 26, 
CP55940-mediated inhibition of migration extended through concentrations as low as 10-
12M, with greater than 50% inhibition observed through 10-10M.  However, the inhibitory 
effect of the agonist began to be reversed by SR2 in cells treated with 10-10M CP55940 
(approximately 25% inhibition compared to 50%) and was totally reversed in cells treated 
with 10-11 and 10-12 M CP55940.   
 
THC Alters Functional Morphology of Murine Peritoneal Macrophages Undergoing 
Chemotaxis to Amoebic Conditioned Medium 
Transwell chemotaxis assays revealed that THC inhibits peritoneal macrophage 
migration to Acanthamoeba conditioned medium.  Similar to results seen of macrophages 
migrating to RANTES, scanning electron microscopy analysis of the transwell 
membranes demonstrated that cells treated with THC were impaired in their ability to 
migrate through the pores into the bottom chamber containing the chemoattractant.  
Vehicle-treated (0.01% Ethanol) peritoneal macrophages exposed to amoeba conditioned 
medium exhibited characteristics indicative of cell migration including lobose cellular 
extensions (Fig. 30).  Additionally, numerous vehicle-treated macrophages were found in 
or near the membrane pores with pseudopodia extending toward the pore (Fig. 30).  In 
contrast, peritoneal macrophages treated with THC were rounded in appearance, with the 
absence of cellular extensions. Few THC-treated macrophages were observed in filter 
pores and those cells that were proximal did not appear to be moving toward the pore. 
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Figure 30– THC Alters the Morphology of Peritoneal Macrophages Migrating to 
Acanthamoeba Conditioned Medium.  Scanning electron microscopy of 
transwell inserts of peritoneal macrophages treated with Vehicle (0.01% 
Ethanol) or THC (10-6 M) (3h) migrating towards Acanthamoeba conditioned 
medium (top row- Acanthamoeba JH1 conditioned medium (JH1CM), bottom 
row- Acanthamoeba culbertsoni conditioned medium).  Note the cellular 
projections of the vehicle-treated macrophages migrating to amoebic conditioned 
medium, whereas the cells treated with THC are rounded in appearance and do 
not appear to be migrating toward the pores.  Scale bars top row left to right 1, 1, 
and 10 μm; bottom row both 10 μm.  
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Treatment with THC and CP55940 Inhibits Rat Primary Microglial Migration to Amoeba 
Conditioned Medium 
 As one of the primary sites of Acanthamoeba infection occurs in the CNS, it was 
important to assess the effect of cannabinoids on migration of primary microglial cells to 
amoebic conditioned medium.  Treatment of primary neonatal rat microglia with THC 
(10-6 -10-8 M) resulted in significant inhibition of migration to Acanthamoeba culbertsoni 
conditioned medium (AcCM; 54μg) (Fig. 31).  Replicate experiments using CP55940 
also resulted in significant concentration-related inhibition of microglial migration to 
Acanthamoeba culbertsoni conditioned medium  (AcCM; 54μg) (Fig. 31).  Similar 
experiments assessing the effect of THC or CP55940 (10-6 M) on microglial migration to 
Acanthamoeba (JH1) conditioned medium also revealed cannabinoid-mediated inhibition 
(data not shown). 
 
The CB2-selective Ligand O-2137 Inhibits Rat Primary Microglial Migration to Amoebic 
Conditioned Medium   
 The inhibitory effect of THC and CP55940 on the migratory response of primary 
microglia to amoebic conditioned medium implicated a role for a cannabinoid receptor.  
Cannabinoid receptor selective agonists therefore were employed to determine the 
cannabinoid receptor associated with this inhibitory effect.  Treatment with O-2137, a 
highly selective CB2 ligand resulted in significant inhibition of microglial migration to 
Acanthamoeba (JH1) conditioned medium (JH1CM; 72 μg) conditioned medium 
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Figure 31- THC and CP55940 Inhibit Chemotaxis of Microglia to 
Acanthamoeba Conditioned Medium. Purified rat microglia were treated for 3 h 
with cannabinoid or vehicle (VEH) (0.01% ethanol) and assessed (2h) for 
migration to Acanthamoeba culbertsoni conditioned medium (AcCM; 54 μg). 
Results are presented as the mean ± SD.  *p<0.05, **p<0.01, ***p<0.001.  
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and Acanthamoeba culbertsoni conditioned medium (AcCM; 54 μg) (Figures 32 and 33, 
respectively).  In contrast, treatment with the CB1 selective ligand had no effect on 
microglial migration to Acanthamoeba (JH1) conditioned medium (JH1CM; 54 μg) 
conditioned medium and Acanthamoeba culbertsoni conditioned medium (AcCM; 54 μg) 
(Figures 32 and 33, respectively).   
  
The CB2-specific Antagonist SR144528 Reverses the Inhibitory Effect of CP55940 on Rat 
Primary Microglial Migration to Amoebic Conditioned Medium 
 To confirm the cannabinoid receptor associated with the inhibitory effect on 
microglial migration, cannabinioid receptor agonist-antagonist experiments were 
performed.  For these experiments, the CB2 antagonist SR144528 (SR2) was used at a 
concentration of 10-6M.  Treatment of primary rat microglia with the CB2-specific 
antagonist SR2 alone had no effect on the chemotactic response to Acanthamoeba 
culbertsoni conditioned medium (AcCM; 54 μg), as the number of SR2-treated cells 
migrating to AcCM was equivalent to the number vehicle-treated cells migrating to 
AcCM (Fig. 34).  CP55940 treatment alone (10-6 and 10-8M) significantly inhibited 
microglial migration to AcCM.  At equimolar concentrations (i.e., 10-6M) of antagonist 
and agonist, CP55940 inhibited macrophage migration to AcCM.  However at lower 
concentrations of agonist (i.e. 10-8M), SR2 reversed CP55940-mediated inhibition.   
   
    71
 
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
C
el
ls
 x
10
3 /m
m
2 / 
W
el
l
* *
*
JH1CM
-6      -7       -8
VEH                         log10M O2137
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6 JH1CM
VEH 10-6 M ACEA     
C
el
ls
 x
10
3 /m
m
2 / 
W
el
l
Figure 32- The CB2 Agonist O-2137 Inhibits Microglial Migration to Acanthamoeba 
Conditioned Medium, but not the CB1 Agonist ACEA.  Microglia were treated (3h) with 
cannabinoid or vehicle (VEH) (0.01% ethanol) and assessed for migration to 
Acanthamoeba (JH1) conditioned medium (2h) (JH1CM; 54 μg). Results are presented 
as the mean ± SD.  *p<0.05.  
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Figure 33-The CB2 Agonist O-2137 Inhibits Microglial Migration to 
Acanthamoeba Conditioned Medium, but not the CB1 Agonist ACEA.  
Microglia were treated (3h) with cannabinoid (10-6M) or vehicle (VEH) (0.01% 
ethanol) and assessed for migration to Acanthamoeba culbertsoni conditioned 
medium (2h) (AcCM; 54 μg). Results are presented as the mean ± SD.  *p<0.05.
 
    
  
73
 
AcCM
1.0
2.0
3.0
4.0
5.0
ce
lls
 x
 1
03
/m
m
2 /w
el
l
VEH -6        -8
CP (log10M)
SR2
-6       -7       -8
CP (log10M)
†††
**
*
*
*
SR2
ce
lls
 x
 1
03
/m
m
2 /w
el
l
Figure 34 – The CB2 Antagonist Reverses CP55940-mediated Inhibition of 
Primary Microglial Migration to Acanthamoeba Conditioned Medium.  Primary 
rat microglial cells were pretreated (30 min) with CB2 antagonist SR2 (10-6 M) 
followed by treatment with 10-6- 10-8M CP55940 (CP) (3h).  Migration to 54 μg A. 
culbertsoni conditioned medium (AcCM) was assessed (2h). Results are presented 
as the mean ± SD. Cannabinoid (CP55940, SR2, and CP55940+SR2) treated 
groups were compared with vehicle (VEH)-treated microglia exposed to 
conditioned medium in the bottom chamber.  *p<0.05, **p<0.01.  Further 
statistical analysis using Bonferroni’s t-test compared groups treated with 
CP55940 (10-6 M) or CP55940+SR2 (10-6 M) to SR2 (10-6 M). ††† p <0.001.      
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Bonferroni’s test was performed for comparisons between treatment groups and further 
confirmed a significant difference in migration to amoebic conditioned medium between 
microglia treated with CP55940 (10-8M) and those treated with CP55940 (10-8M) and 
SR2 (10-6M).   
 These experiments were complemented with those using the CB1 antagonist 
SR141716A (SR1).  For these experiments, CB1 antagonist SR141716A (SR1) was used 
at a concentration of 10-6M.  Treatment of primary rat microglia with the CB1-specific 
antagonist SR1 alone had no effect on the chemotactic response to Acanthamoeba 
culbertsoni conditioned medium (AcCM; 54 μg), as the number of SR1-treated cells 
migrating to AcCM was equivalent to the number of vehicle-treated cells migrating to 
AcCM (Fig. 35).  As observed in the previous experiment using SR2 (Fig. 34), CP55940 
treatment alone (10-6 and 10-8M) significantly inhibited microglial migration to AcCM.  
At equimolar concentrations (i.e., 10-6M) of antagonist and agonist, CP55940 inhibited 
macrophage migration to AcCM.  However, treatment with the CB1 antagonist SR1 was 
unable to block the inhibitory effect of CP55940.   
 
Discussion 
THC, the major psychoactive component in marijuana, has been shown to alter 
the activities of macrophages and macrophage-like cells, including phagocytosis 
(Friedman et al., 1986; Lopez-Cepero et al., 1986; Tang et al., 1992; Ehrhart et al., 
2005), antigen processing (McCoy et al., 1995; McCoy et al., 1999), and production of  
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Figure 35– Pretreatment with the CB1 antagonist SR1 Does Not Alter CP55940-
Mediated Inhibition of Primary Microglial Migration to Acanthamoeba 
conditioned medium.  Primary microglia were pretreated with SR1 (30 min) 
followed by treatment with CP55940 (CP) (3h).  Migration to 54 μg A. culbertsoni 
conditioned medium (AcCM) was assessed (2h).  Results are presented as the 
mean ± SD. Cannabinoid (CP55940, SR1, and CP55940+SR1) treated groups 
were compared with vehicle (VEH)-treated microglia exposed to conditioned 
medium in the bottom chamber.  *p<0.05, **p<0.01, ***p<0.001.  Further 
statistical analysis using Bonferroni’s t-test compared groups treated with 
CP55940 (10-6 M) or CP55940+SR1 (10-6 M) to SR1 (10-6 M). ††† p <0.001 and 
†† p 0.002.      
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chemokines and cytokines (Watzl et al., 1991; Zheng et al., 1992; Puffenbarger et al., 
2000).  Recent studies indicate that this exogenous cannabinoid, as well as other 
cannabinoids, also affects the migratory activities of macrophages.  Stefano et al. (1998) 
reported that acute exposure to the endogenous cannabinoid (endocannabinoid) 
anandamide resulted in transformation of macrophages from an amoeboid and motile 
state to that of a rounded and non-motile conformation.  These investigators proposed 
that the transforming events were linked to the CBB1 receptor since the CB1-specific 
antagonist SR141716A blocked the transformation.  Sacerdote et al. (2000) demonstrated 
that in vivo and in vitro treatment of rat peritoneal macrophages with CP55940, a high 
efficacy agonist at both CB1 and CB2 receptors, resulted in decreased migration in vitro 
to the peptide formal-methionyl-leucine-phenylalanine (fMLP).  It was indicated that, 
while both the CB1 and CB2 receptors appeared to be involved in this process, the 
cannabinoid-mediated effect was linked primarily to the CB2.  The chemotactic response 
of murine macrophages to fMLP also has been shown to be decreased by cannabidiol 
(Sacerdote et al., 2005), a cannabinoid that binds weakly to CB2.  The CB2 antagonist 
SR144528 prevented this decrease, suggesting a functional linkage to this receptor.   
On the other hand, Walter et al. (2003) found that the endocannabinoid 2-
arachidonylglycerol (2-AG) triggered migration of microglia, macrophages that are 
resident in the brain, and that the CB2 was involved in this effect.  Additionally, these 
investigators and others (Jorda et al., 2002; Kishimoto et al., 2005) have demonstrated 
that THC did not induce a migratory cellular response in natural killer cells or cells of 
myeloid origin and, further, inhibited migration of these cell types to 2-AG.  Collectively, 
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these studies suggest that exogenous cannabinoids exert inhibitory effects on macrophage 
migration while endocannabinoids elicit an opposite effect.  
 Consistent with these observations, in the present study we demonstrated that 
THC inhibits the chemotactic or directed migratory response of murine peritoneal 
macrophages to RANTES, a chemokine that can signal through the chemokine receptors 
CCR1 and CCR5.  This effect was exerted on peritoneal macrophages from mice 
administered THC in vivo or on peritoneal macrophages that were exposed directly to 
THC in vitro.  In the latter context, the inhibition occurred over a wide concentration 
range (i.e., 10-6 M – 10-12 M).  These results are consistent with THC as having a direct 
effect on macrophages which results in inhibition of chemotaxis.  Indeed, scanning 
electron microscopic analysis revealed dramatic alterations in cellular morphology 
following treatment with THC, indicating that these cells had reduced migratory 
responsiveness.  Whereas vehicle-treated cells migrating to RANTES displayed 
morphological characteristics of migration including membrane ruffling and numerous 
cellular projections extending toward or into membrane pores, the cells treated with THC 
were rounded and appeared to be non-motile.   
The results obtained with THC were replicated using the high efficacy CB1/CB2 
agonist CP55940.  Treatment of murine macrophages in vitro with CP55940 resulted in 
inhibition of chemotaxis to RANTES over the same concentration range (i.e., 10-6 M – 
10-12 M) of THC.  In order to establish whether the cannabinoid-mediated inhibition was 
linked to a cannabinoid receptor, a series of experiments was performed in which 
cannabinoid receptor-selective agonists as well as cannabinoid receptor-specific 
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antagonists were used.  Treatment of macrophages in vitro with O-2137, a compound that 
exhibits high selectivity for the CB2, resulted in a robust inhibition of macrophage 
chemotaxis.  In contrast, the CB1 selective compound ACEA had a minimal effect.  In 
addition, the CB2 antagonist SR144528 blocked CP55940-mediated inhibition of 
macrophage chemotaxis while the CBB1 antagonist SR141716A had a minimal effect. 
Finally, THC was not able to inhibit the chemotactic response to RANTES of peritoneal 
macrophages obtained from CB2 knockout mice.  Collectively, the results of experiments 
in which a pharmacological approach was complemented with that using macrophages 
from CB2B  null (i.e., CB2 -/-) mice support the proposition that the CB2 is linked 
functionally to the THC-mediated inhibition of chemotaxis to RANTES.  
RANTES, for which the current International Union of Pharmacology 
nomenclature is CCL5 (Murphy, 2002), is one of many chemotactic cytokines that direct 
the migration of leukocytes to sites of infection and inflammation.  In this capacity, these 
small molecular weight proteins constitute a critical component of innate immune 
defenses.  Four subfamilies of chemokines have been identified based on the relative 
position of their N terminal cysteine residues.  All chemokines bind specific receptors 
that have seven transmembrane domains and are coupled to heterotrimeric Gi proteins, a 
feature that is shared with cannabinoid agonists.  However, binding within a chemokine 
subfamily is somewhat promiscuous. In addition, multiple chemokine receptor types have 
been identified on individual immune cells and their expression may vary in relation to 
cell differentiation and activation. These characteristics confer multiple levels of 
regulation and exquisitely sensitive responses to the chemokine/chemokine receptor 
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system.  RANTES, for example, can bind CCR1, CCR3, and CCR5, receptors that have 
specialized roles in leukocyte trafficking (Murdoch and Finn, 2000; Murphy, 2002; 
Charo et al., 2006).  Monocytes have been reported to express a variety of chemokine 
receptors, particularly CCR1, CCR2, and CCR5 (Mantovani et al., 2004).  It has been 
demonstrated also that differentiation of monocytes into tissue macrophages is associated 
with the upregulation of CCR1 and CCR5 and loss of CCR2 expression (Mantovani et 
al., 2004).  In the present study, we examined thioglycollate-elicited peritoneal 
macrophages from (B6C3)F1 and C57BL/6 mice for their CC chemokine receptor 
expression profile.  These cells were shown to express CCR1 and CCR5, receptors that 
can bind RANTES.  Thus, in the context of our experimental paradigm it is possible that 
RANTES acted through one or both receptors to induce chemotactic activity.  In turn, 
THC may have affected the functionality of one or both chemokine receptors.  Regardless 
of which of the chemokine receptors found on macrophages is functionally relevant in 
RANTES-mediated signaling, the results of this study suggest that cannabinoid activation 
of the CB2 can result in deactivation of other members of the G protein-coupled family 
such as chemokine receptors.  Further studies utilizing chemokine receptor-specific 
antagonists should serve to identify the CC receptor type that is linked to RANTES-
mediated chemotactic activity that is targeted by cannabinoids.  
 The mode by which THC and other analogs that signal through cannabinoid 
receptors to deactivate CCR1 and/or CCR5 chemokine receptor migratory responsiveness 
to RANTES remains to be defined.  THC and other cannabinoids, as highly lipophilic 
molecules, can perturb cellular membranes (Martin, 1986; Makriyannis et al., 1990; 
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Cabral and Staab, 2005).  Such perturbation could alter conformational strictures 
requisite for ligand-receptor interaction, disrupt receptor-G protein complexes, and 
disturb intracellular membranous compartments that are linked to biochemical events in 
the cascade of signal transduction.  However, as suggested by the present study, 
cannabinoids also may trans-deactivate chemokine receptors and affect their ability to 
elicit a signal transductional cascade that culminates in the chemotactic migratory 
response.  Indeed, it has been reported that members of the G protein coupled receptor 
superfamily can associate with each other, forming homodimers and heterodimers that 
results in alteration in the functionality of one of the involved receptors (Rios et al., 
2001).  Opioid receptors, for example, have been reported to interact with chemokine 
receptors to alter their function.  Grimm et al. (1998) indicated that this interaction 
resulted in trans-deactivation of chemokine receptors and that it occurred through a 
process of receptor-mediated heterologous desensitization.  Desensitization is the 
functional result of receptor phosphorylation by G protein coupled receptor kinases 
(GRKs) or other second messenager kinases (i.e., protein kinase C), which prevents 
further coupling to G proteins.  Following arrestin binding, the phosphorylated receptor 
undergoes internalization and recycling.    
In their studies, Grimm et al. (1998) demonstrated that met-enkephalin and 
morphine inhibited interleukin (IL)-8-induced chemotaxis of human neutrophils and 
macrophage inflammatory protein (MIP)-1α, RANTES, and monocyte chemoattractant 
protein (MCP)-1-mediated chemotaxis of human monocytes.  This inhibition was 
indicated as mediated by δ- and μ-opioid receptors, the activation of which led to 
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phosphorylation of the chemokine receptors CXCR1 and CXCR2 resulting in 
heterologous desensitization.  Rogers et al. (2000) reported that activation of opioid and 
chemokine receptors could lead to reciprocal down-regulation of leukocyte migratory 
activities.  These observations have been extended using a number of experimental 
paradigms (Szabo and Rogers, 2001; Szabo et al., 2001; Szabo et al., 2002; Suzuki et al., 
2003; Zhang et al., 2003).  Indeed, it has been proposed that cross-desensitization of 
chemokine receptors by opioids represents a significant element in opioid-mediated 
immunosuppression (Zhang et al., 2003).  The process of heterologous desensitization 
may also apply to cannabinoid receptors, and these studies may serve to elucidate, in part, 
the mechanism of cannabinoid-mediated immunosuppression. Ghosh et al. (2006) 
reported that the CB1/CB2 agonist CP55940, as well as the CBB2-selective agonist JW-015, 
caused significant inhibition of chemokine CXCL12-induced chemotaxis of CD4+ and 
CD8+ T lymphocytes.  These investigators also found that these cannabinoids inhibited 
CXCL12 induced chemotaxis and transendothelial migration of Jurkat T cells. Rios et al. 
(2006) reported recently that the μ opioid receptor also interacts with the CB1B  to affect a 
reciprocal inhibition of receptor signaling and receptor-induced neuritogenesis.  
In the present study, we propose that heterologous desensitization may articulate a 
mode of action by which cannabinoids mediate inhibition of the murine peritoneal 
macrophage chemotactic response to RANTES.  Thus, in order to obtain initial insight as 
to the process by which THC and other cannabinoids cross-deactivate this macrophage 
activity, a multiprobe RNase protection assay was performed to assess for levels of CC 
chemokine receptor mRNAs. THC over a concentration range of 10-6M to 10-12M had no 
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effect on macrophage mRNA levels of CCR1 and CCR5.  Likewise, treatment with other 
cannabinoid receptor agonists and antagonists including CP55940, SR1 and SR2 (10-6M) 
had no effect on CCR1 or CCR5 mRNA as assessed by multiprobe RNase protection 
assay.  These results are consistent with THC-mediated inhibition of the chemotactic 
process as occurring at a level of regulation other than gene expression of the cognate 
receptors at the mRNA level.  Immunoprecipitation experiments followed by Western 
blot analysis using a primary antibody specific for phosphorylated serine residues were 
performed to assess for effects of cannabinoids on protein expression and 
phosphorylation of CCR5, which notably undergoes serine phosphorylation.  Stimulation 
with the cognate ligand RANTES induced CCR5 phosphorylation as compared to cells 
treated with vehicle.  Further, treatment with CP55940 (10-6M) resulted in the induction 
of CCR5 phosphorylation.  The level of CCR5 phosphorylation induced by CP55940 was 
less than the level of phosphorylation following stimulation with RANTES, results which 
are consistent with reports by Chen et al. (2004) who demonstrated that treatment with μ-
opioid receptor agonist DAMGO induced CCR5 phosphorylation but to a lesser extent 
than RANTES. 
Cannabinoids can also affect migration to chemotactic molecules other than 
chemokines including bioactive lipids such as 2-AG.  2-Arachidonoylglycerol (2-AG) is 
an endogenous cannabinoid (endocannabinoid) that is a native ligand to cannabinoid 
receptors in the CNS and in the periphery.  Formation of 2-AG occurs rapidly through the 
cleavage of membrane phospholipids by phospholipases and diacylglycerol lipase.  It is 
produced by numerous cell types under a wide variety of stimulatory conditions including 
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LPS stimulation of rat macrophages (DiMarzo et al., 1999), ATP stimulation of mouse 
microglia (Witting et al., 2004), cholera toxin-treated mouse small intestine (Izzo et al., 
2003), macrophage colony stimulating factor treated rat microglia (Carrier et al., 2004), 
and mouse brain following traumatic brain injury (Panikashvili et al., 2001).  Indeed, it 
has been proposed that 2-AG plays a physiological role in the regulation of 
neurotransmitter release (Sugiura and Waku, 2000), the cardiovascular system (reviewed 
in Sugiura et al., 2006), and the proliferation and invasion of certain types of cancer cells 
(reviewed in Sugiura et al., 2006).  It seems very likely, therefore, that 2-AG plays an 
essential role in the regulation of a variety of biological systems.   
Accumulating evidence also suggests that 2-AG is involved in 
immunomodulation.  Kishimoto et al. (2004) reported that 2-AG induced production of 
interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1), and that this 
effect was linked to CB2.  Further, addition of LPS to 2-AG synergistically augmented 
IL-8 and MCP-1 production.  2-AG has also been shown to modulate other activities 
associated with the inflammatory response inducing changes in cellular morphology 
through rapid actin rearrangement (Gokoh et al., 2005), enhancing cellular adhesion 
(Gokoh et al., 2005), and stimulating cell migration.   Walter et al. (2003) demonstrated 
that 2-AG induced migration in microglia, and that this migration was linked to activation 
of CB2.  Further, localization of CB2 to the leading edge of lamellipodia implicated a role 
for CB2 in migration (Walter et al., 2003).  Additional studies (Jorda et al., 2002; 
Kishimoto et al., 2005) demonstrated that 2-AG induces migration in multiple immune 
cell types and that treatment with THC can inhibit this migration.  It has recently been 
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proposed by Cabral et al. (2007) that cannabinoids alter macrophage migration through 
activation of CB2, with endocannabinoids such as 2-AG exerting a stimulatory effect and 
exogenous cannabinoids eliciting an opposite, inhibitory effect.  Endogenous 
cannabinoids such as 2-AG, signaling through CB2, may stimulate or support an 
inflammatory response through the increase in cell adhesion and migration, the activation 
of mitogen-activated protein kinase (MAP kinase), induction of [Ca2+] release, and 
upregulation of chemokine production whereas other CB2 ligands may block these 
effects.  This block could be the result of competition for receptor binding involving 
limiting factors such as ligand accessibility (generation and short half-life of endogenous 
ligands) or ligand affinity.   
As a critical component in innate immunity, macrophages play a key role in 
recognition and clearance of bacterial, protozoan, and viral pathogens.  Integral to this 
recognition process are a host of cellular receptors.  For example, pattern recognition 
receptors recognize pathogen associated molecular pattern (PAMPs), which include 
bacterial carbohydrate moieties like mannose or LPS; bacterial, viral, protozoan RNA or 
DNA; and viral glycoproteins.  Host cells also express a class of G-protein coupled 
receptors designated Protease-activated receptors (PARs1-4) that can be activated by 
immune cell-derived or microorganism-derived serine proteases (Steinhoff et al., 2005; 
Traynelis and Trejo, 2007).  PAR1and PAR2 can coupled to Gαq, Gαi, Gα12/13, and Gβγ 
and induce multiple signal transduction cascades. PAR1/2 activation induces protein 
kinase C (PKC) and MAP kinase activation, Rho/Rac signaling, mobilization of 
intracellular calcium [Ca2+] through activation of phospholipase C (PLC), and activation 
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of receptor tyrosine kinases (RTKs) (Traynelis and Trejo, 2007).  Activation of these 
signaling networks results in alterations in cell shape, adhesion, secretion of 
inflammatory mediators, and motility.  PAR1 is expressed in a variety of cells including 
platelets, endothelial cells, CD8+ T cells, monocytes, migroglia, astrocytes, neurons, 
mast cells, and certain tumor cells (reviewed in Steinhoff et al., 2005).  PAR2 is 
expressed by immune cells including dendritic cells, eosinophils, macrophages, and 
neutrophils (Miike et al., 2001; Colognato et al., 2003; Howells et al., 1997; Moormann 
et al., 2006).  Serine proteases and PARs have been implicated in immune and 
inflammatory regulation; however, the majority of the data to date is limited to PAR 
modulation of cell adhesion molecules, chemokine/cytokine production, and cell 
migration.  Colotta et al. (1994) reported that thrombin, acting through PAR1, induced 
expression of MCP-1 by human peripheral blood mononuclear cells (PBMC). 
Additionally, treatment of endothelial cells with thrombin, which signals through PAR1, 
induced IL-8, E-selectin (Kaplanski et al., 1997), intercellular adhesion molecule-1 
(ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) expression (Kaplanski et 
al., 1998).  PAR1 activation with thrombin has also been shown to induce human 
neutrophil chemotaxis (Mariano-Oliveira et al., 2007).  Morris et al. (2006) demonstrated 
that PAR2 plays a critical role in breast cancer cell migration and invasion.   
Many bacteria and amebae that are pathogenic in humans produce serine 
proteases.  It is reasonable, therefore, to postulate that these pathogen-derived proteases 
may trigger specific immune or inflammatory responses through direct interaction with 
host cell PARs.  Amebae of the genus Acanthamoeba have been shown to secrete 
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multiple serine, cysteine, and matrix metalloproteases that have been implicated in the 
virulence of the pathogen (Marciano-Cabral and Cabral, 2003).  These proteases are 
thought to play a role in tissue destruction and pathogen invasion, and are capable of 
degrading host IgA and IgG, multiple extracellular matrix components including types I 
and III collagen, and serum proteins hemoglobin and fibrinogen (Kong et al., 2000; Mitro 
et al., 1994; Cho et al., 2000; and Sissons et al., 2006).  In the present study we 
demonstrated that peritoneal macrophages migrate towards media conditioned with two 
strains of Acanthamoeba (Acanthamoeba culbertsoni and Acanthamoeba JH1, which 
contains intracellular gram negative bacteria).  Acanthamoeba conditioned medium has 
been shown to contain a variety of proteases including serine and metalloproteases 
(Sissons et al., 2006).  The chemoattractants in the amoebic conditioned medium seem to 
be directly produced by the amoeba, as there was no major difference in cell migration to 
the conditioned medium derived from culture with Acathamoeba culbertsoni or from 
medium cultured with Acanthamoeba JH1 harboring intracellular bacteria.  We also 
found that THC inhibits the chemotactic response of murine peritoneal macrophages to 
Acanthamoeba conditioned medium. This inhibitory effect was exerted on peritoneal 
macrophages from mice administered THC in vivo or on peritoneal macrophages that 
were exposed directly to THC in vitro.  Scanning electron microscopic analysis revealed 
dramatic alterations in macrophage morphology following treatment with THC, 
indicating that these cells had reduced migratory responsiveness similar to previous 
results obtained using RANTES as the chemoattractant.  Vehicle-treated cells migrating 
to Acanthamoeba conditioned medium displayed morphological characteristics of 
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migration including membrane ruffling and numerous cellular projections extending 
toward or into membrane pores; however, as demonstrated in previous studies the 
macrophages treated with THC appeared to be rounded and non-motile.   
 We then employed a strategy similar to the one previously utilized in the 
RANTES studies to determine whether a cannabinoid receptor was involved in inhibition 
of macrophage migration to amoebic conditioned medium.  Experiments were repeated 
using the high efficacy CB1/CB2 agonist CP55940.   Treatment of peritoneal 
macrophages in vitro with CP55940 resulted in significant inhibition of migration to 
Acanthamoeba conditioned medium.  In addition, we performed experiments using 
compounds exhibiting selective high affinity binding to the CB1 or the CB2 prior to 
assessment of the chemotactic response to amoebic conditioned medium (ACEA and O-
2137, respectively).  Treatment of macrophages with the selective CB2 ligand O-2137 
resulted in significant concentration-related inhibition in the migration to Acanthamoeba 
conditioned medium.  The CB1 specific ligand ACEA had no effect on peritoneal 
macrophage migration to Acanthamoeba conditioned medium.  Further experiments 
employing cannabinoid receptor antagonists used in concert with CP55940 were 
performed.  The CB2 antagonist SR144528 blocked CP55940-mediated inhibition of 
macrophage migration to amoebic conditioned medium while the CB1 antagonist 
SR141716A had a minimal effect.  Together, these results imply that CBB2 is linked to 
cannabinoid-mediated inhibition of macrophage migration to Acanthamoeba conditioned 
medium.   
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 For many years the brain was believed to be an immune privileged site, however 
accumulating evidence suggests that, like the periphery, the CNS is under constant 
immune surveillance.  Microglia are a resident population of cells in the CNS that are 
morphologically, phenotypically, and functionally related to macrophages (Aloisi, 2001; 
Gehrmann et al., 1995). Upon activation by inflammatory or infectious stimuli, these 
cells undergo proliferation and functional maturation with alterations in receptor 
expression and the production of inflammatory mediators like cytokines, chemokines, 
and reactive oxygen species (Aloisi, 2001).  Dysregulation of this response, or chronic 
activation, has been implicated in neuropathological diseases like Multipe Sclerosis 
(MS), Alzheimer’s disease (AD), Parkinson’s disease, and Acquired Immune Deficiency 
(AIDS) dementia (reviewed in Bajetto et al., 2002).   
 A signature activity of activated microglia is migration to sites of inflammation or 
infection.  Using a mouse model of Acanthamoeba infection in the CNS, Cabral et al. 
(2007) demonstrated the involvement of macrophage-like (microglia) cells in the 
formation of immune cell granulomas surrounding Acanthamoeba culbertsoni cysts.  
Granulomas are believed to sequester pathogens preventing further dissemination.  Mice 
administered THC in vivo experienced higher rates of mortality following infection with 
the amoebae which may be due, in part, to the observed inability to form granulomas.  
We postulated that the absence of granulomas following THC might be the consequence 
of a cannabinoid-mediated inhibition of microglial migration.  In the final part of the 
study, we utilized an in vitro migration system with primary rat microglial cells and 
Acanthamoeba conditioned medium to model an in vivo infection and assess the effect of 
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THC on microglial migration.  Treatment of primary neonatal rat microglia with THC or 
CP55940 (10-6-10-8M) resulted in significant concentration-related inhibition of 
microglial migration to Acanthamoeba conditioned medium.   
Carlisle and Cabral (2002) reported that microglia constitutively express very low 
levels of CB1, whereas CBB2 is expressed differentially in relation to cell activation state.  
CB2 is expressed at high levels in microglia when they are in responsive or primed states.  
These activation states are characterized by differential gene expression and certain 
functional activities.  In responsive and primed states macrophages and microglia are 
capable of chemotaxis, phagocytosis, and antigen presentation, activities that correlate 
with early inflammatory responses.  We performed migration assays using compounds 
exhibiting selective binding to the CB1 or the CB2 prior to assessment of the chemotactic 
response to amoebic conditioned medium.  Treatment of macrophages with the CB2 
ligand O-2137 resulted in significant concentration-related inhibition in the migration to 
Acanthamoeba conditioned medium; however, the CB1 specific ligand ACEA had no 
effect on microglial migration to Acanthamoeba conditioned medium.  Further 
experiments using CB1 and CB2 specific antagonists in combination with CP55940 were 
also performed.  Treatment with the CB2 antagonist SR144528 blocked CP55940-
mediated inhibition of microglial migration to amoebic conditioned medium while the 
CB1 antagonist SR141716A had no effect.  These data suggest cannabinoid-mediated 
inhibition of microglial migration to Acanthamoeba conditioned medium is linked to the 
CB2 cannabinoid receptor, which is consistent with the known cannabinoid receptor 
expression profile of microglia, as well as the results from previous models used in our 
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studies.  Furthermore, since migration can be elicited by protease activation of PARs on 
microglia, it is possible that THC-mediated inhibition of the chemotactic response to 
amoebic conditioned medium may be due to CB2 “cross-talk” with PARs.  Studies to 
establish such a functional linkage should serve to clarify whether the CB2 receptor can 
“cross-communicate” with a diverse array of G-protein coupled receptors so as to 
modulate responsiveness by macrophages and macrophage-like cells.   
 In summary, we have demonstrated that THC and other exogenous cannabinoids 
that activate the CB2 inhibit murine peritoneal macrophage chemotaxis to 
RANTES/CCL5.  This inhibitory effect was linked functionally to the CBB2 receptor.  
Furthermore, since this chemokine serves as a ligand for CCR1 and CCR5, these results 
suggest that activation of the CB2 leads to trans-deactivation of these G protein-coupled 
receptors of the CC chemokine subfamily that have specialized roles in leukocyte 
trafficking.  Thus, as has been suggested for opioid receptors, CB2 “cross-talk” with 
chemokine receptors may constitute an integrative component of a network of 
intercommunicating G protein-coupled receptors that regulate immune responses.  In 
addition, we have demonstrated that THC and other exogenous cannabinoids that activate 
the CB2 inhibit murine peritoneal macrophage and rat primary microglial chemotaxis to 
Acanthamoeba conditioned medium.  Cannabinoids, as acting through cannabinoid 
receptors, may “cross-communicate” with a diverse array of G-protein coupled receptors, 
thereby affecting activation of receptors such as CCR5 and PARs.  Although much more 
work needs to be done to link the chemotactic response of macrophages and microglia to 
amoebic conditioned medium to PAR activation and to establish whether heterologous 
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desensitization is occurring between CB2 and PARs, this study provides initial insight to 
the mechanism of THC-mediated immunosuppression in CNS infections with amoeba.     
We also have shown that the endogenous cannabinoid, 2-AG induces migration of 
peritoneal macrophages and that this effect can be inhibited by the exogenous 
cannabinoid, THC.  We have proposed a model in which endogenous cannabinoids 
signaling through CB2 exert a positive or stimulatory effect on the inflammatory 
response, whereas exogenous cannabinoids elicit an inhibitory effect.  These studies 
demonstrate a critical role for CB2 in immunoregulation and inflammation in the CNS 
and the periphery.   
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